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General Introduction 
 
Subcortical ischaemic vascular disease 
Vascular dementia is considered the second most common type of dementia, 
accounting for ten to fifty percent of all dementia cases. The major subtypes of 
vascular dementia are cortical vascular dementia, strategic infarct dementia and 
subcortical vascular dementia, each of which has unique aetiological 
mechanisms and manifestations. The concept of vascular dementia covers a 
wide spectrum of cognitive dysfunction, ranging from subtle and clinically 
often undetected deficits to overt dementia1. Clinically important cognitive 
impairments that are associated with vascular disease frequently do not fulfil 
the traditional criteria for dementia, as these criteria tend to be based on the 
context of Alzheimer’s disease and require the presence of prominent memory 
impairment2,3. Early diagnosis is impossible, as patients must fulfil the clinical 
criteria for dementia. The concept of vascular cognitive impairment was 
therefore introduced to refer to all forms of cognitive impairment, ranging from 
mild to severe cognitive deficits due to cerebrovascular disease4,5. Because of 
the different clinical symptoms of vascular cognitive impairment and the 
heterogeneity of the aetiological mechanisms, the specific concept of 
subcortical ischaemic vascular disease (SIVD) has been suggested as the most 
prevalent subtype of vascular cognitive impairment. This syndrome has been 
defined by clinical symptoms and specific features on magnetic resonance 
imaging (MRI) and has been described in multiple studies1,6-9.  
 
SIVD is caused by small-vessel disease, which results in cerebral white-matter 
lesions (WML) and lacunar infarcts in subcortical white and grey matter, as 
demonstrated by MRI of the brain1,8,10. Because individuals who suffer from 
SIVD frequently do not fulfil the traditional criteria for vascular dementia 
(according to the criteria from the National Institute of Neurological Disorders 
and Stroke and the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences [NINDS-AIREN]11) diagnostic consensus 
criteria have been introduced for the cognitive syndrome of SIVD12. The 
neuropsychological profile is characterized by early impairment of attention 
and executive function, with a slowing of motor performance and information 
processing. Although episodic memory is believed to remain relatively 
unaffected, depression, emotional lability and apathy are particularly frequent 
in these patients, as compared to those who suffer from AD12. In addition, these 
modified criteria do not require any clear temporal relation between the onset 
of cognitive impairment and vascular disease, as the onset of vascular cognitive 
impairment due to SIVD is frequently more insidious. Because empirical data 
describing the clinical and cognitive manifestations of SIVD are still sparse, 
there is a pressing need to validate and further refine these criteria9,10.  
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The assessment of cognitive impairment caused by SIVD poses a challenge for 
both clinicians and investigators. Patients with SIVD often do not present with 
marked focal neurological deficits or abrupt deterioration in cognitive 
functions. The subtle clinical symptoms are often neglected by physicians, and 
both patients and physicians tend to consider these symptoms as normal signs 
of ageing. Because of the distinct cognitive profiles of patients with SIVD, 
these deficits are not detected by screening tests, such as the Mini Mental State 
Examination (MMSE)13, the Seven Minute Screening test14 and the Memory 
Impairment Screen (MIS)15, as these tests were designed to identify the 
cognitive symptoms of Alzheimer’s disease (AD). Because of the frequency 
with which SIVD is identified as a cause of vascular cognitive impairment, 
there is need for a brief and simple cognitive screening test in order to allow 
early diagnosis and to facilitate the recognition of cognitive problems in 
everyday practice with patients who are at risk for SIVD. 
 
Risk factors for SIVD 
Subcortical ischaemic vascular disease (SIVD) is caused by small-vessel 
disease with cerebral white-matter lesions (WML) and lacunar infarcts in 
subcortical white and grey matter as the primary type of brain lesions on MRI 
(Figure 1, see page 3). WML on MRI scans of the brain are clearly associated 
with age16,17; this finding is consistent throughout all studies that have 
investigated large numbers of individuals across a sufficiently wide age range. 
The association of WML with cerebrovascular risk factors, however, is less 
straightforward16,17. Although associations with arterial hypertension have been 
frequently described, other cerebrovascular risk factors, including diabetes 
mellitus (DM), cardiac disease or smoking have been less frequently identified 
as possible contributors to the development of WML16,18. Many studies have 
had major methodological limitations, including small sample size, inability to 
adjust for confounding factors and unclear operationalization of risk factors and 
structural brain changes.  
 
Type 2 DM and cognitive decline in the elderly are major public health 
problems. More than ten percent of all elderly people suffer from Type 2 DM, 
and cross-sectional studies have suggested that cognitive impairment and DM 
are interrelated with each other19. The neuropsychological studies that establish 
this relation lack neuro-imaging data, however, and neuro-imaging studies 
largely lack any assessment of cognition. To provide important clues to the 
pathogenesis, it is important to combine these assessment modalities, in order 
to establish how DM may affect the structural integrity of the brain. This may 
ultimately lead to the development of therapeutic strategies that can prevent 
accelerated cognitive decline in DM patients. 
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1a.   1b. 1c. 1d. 
Figure 1. Axial fluid attenuated inversion recovery (FLAIR) of periventricular and deep white-
matter lesions (a, b,c) and lacunar infarcts (d) 
 
Aims of the thesis 
 
The general objective of this thesis was to investigate clinical aspects of 
patients with subcortical ischaemic vascular disease (SIVD) and associations 
with Type 2 diabetes mellitus (DM). To this end, we validated a newly 
developed cognitive screening test for use with these patients, and we 
investigated the value of a clinical neurophysiological test. In addition, we 
investigated the association between Type 2 DM and cognitive impairment due 
to SIVD.  
 
It is known that the generally accepted cognitive screening tests are not able to 
detect cognitive decline in patients with SIVD. We therefore attempted to 
validate the Human Immunodeficiency Virus (HIV) dementia scale (HDS)20 in 
elderly SIVD patients. The HDS is a reliable and quantitative scale for 
identifying HIV dementia, which has a profile with subcortical features 
comparable to that of SIVD. We hypothesized that this test would be able to 
detect cognitive impairment in patients with SIVD and that this test would be 
superior to the MMSE and other widely used bedside tests. The results are 
described in Chapter 2. In Chapter 3 we investigated whether a clinical neuro-
physiological test (similar to the the Auditory Oddball Paradigm), which has 
prolonged latencies of different deflections (e.g. N200 and P300) in dementia, 
could differentiate between patients with vasculair cognitive impairment (VCI) 
caused by SIVD in an early phase of the disease and age-matched control 
subjects. If so, both tests could contribute to the diagnosis of cognitive 
impairment in patients who are at risk for SIVD.  
 
Second, hypertension is the most important and consistent risk factor for white-
matter disease and lacunar infarcts16. DM is a known risk factor for vascular 
disease and increases the risk of cerebral large-vessel disease, leading to 
stroke21,22. Data on the association between small-vessel disease and DM are 
not consistent, however, and correlations of subcortical structural brain lesions 
with cognitive decline in Type 2 DM have never been investigated. In Chapter 
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4, we performed a systematic review of the literature addressing the association 
between DM and changes on brain imaging, including SIVD. In Chapter 5, we 
investigated the association between Type 2 DM and changes on brain imaging 
within a well-defined group of independently living elderly patients with Type 
2 DM. We hypothesized that concomitant hypertension could be defined as a 
relevant disease variable in DM patients and that DM is not an independent risk 
factor. In Chapter 6, we performed a cross-sectional case-control study in a 
well-defined group of elderly patients living independently at home with Type 
2 DM, in order to describe the neuropsychological profile in detail. We also 
investigated the relationships between cognitive performance in DM patients 
and such MRI measures as WML, lacunar infarcts, medial temporal lobe 
atrophy (MTA) and cerebral atrophy, which are often associated with cognitive 
decline and dementia in general. 
 
The main conclusions are summarized and discussed in the last chapter. 
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Abstract 
 
Introduction: 
Most cognitive screening instruments are tailored to detect symptoms of 
cortical dysfunction in the elderly. Therefore, subcortical cognitive dysfunction 
may be missed using these tests. The aim of this study was to validate the 
Human Immunodeficiency Virus (HIV) Dementia Scale (HDS), a screening 
test developed to detect subcortical cognitive dysfunction in young HIV-
infected patients, in a group of elderly patients with subcortical cognitive 
impairment (SCI) caused by subcortical ischaemic vascular disease (SIVD) or a 
normal pressure hydrocephalus (NPH). 
 
Materials and methods: 
53 patients with SCI caused by SIVD or a NPH and 54 age-matched control 
subjects without cognitive impairment were included. All subjects underwent 
the HDS and the Mini-Mental State Examination (MMSE). A neuropsycho-
logical examination was used as the best reference test for the diagnosis of SCI. 
 
Results: 
The mean HDS score (maximum 16) was 5.1 ± 3.5 in the SCI patients and 13.0 
± 2.4 in the controls (p<0.0001). The mean MMSE score (maximum 30) was 
26.5 ± 3.1 in the SCI group and 28.6 ± 1.4 in the controls (p<0.0001). Among 
subjects, who had an MMSE score of more than 26 points, SCI patients (n=35) 
also scored significantly lower (p=0.002) on the HDS than controls (n=50), 
mean scores being 6.2 ± 3.4 and 13.0 ± 2.4, respectively (p<0.0001). 
A receiver-operating characteristics curve was used to detect the optimal 
sensitivity and specificity of the HDS. A cut-off score of 9 yielded 91% 
sensitivity (95% CI: 79-97) and 96% specificity (95% CI: 87-99). With this cut-
off score, the positive predictive value was 96% (95% CI: 86-99) and the 
negative predictive value was 91% (95% CI: 81-97). 
 
Conclusions: 
These results suggest that the HDS is able to detect SCI in an elderly 
population with SIVD or NPH and a normal MMSE, and warrant its further 
development as a screening tool for SCI. 
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Introduction 
 
As the aged population grows, cognitive decline is a public challenge of 
increasing importance. Nevertheless, it has been demonstrated that cognitive 
impairment remains unrecognized by primary care clinicians and physicians 
until the disease is well advanced1.  Adequate care and future therapeutic inter-
ventions require that the impairment is recognized and its cause determined at a 
very early stage. This emphasizes the need for brief and simple screening tests, 
which could facilitate recognition of cognitive problems in everyday practice. 
Most screening tests, however, like the Mini-Mental State Examination 
(MMSE)2, the Seven-Minute Screening Test3 and the Memory Impairment 
Screen (MIS)4 have been tailored to the recognition of cognitive symptoms 
with cortical features as in Alzheimer’s disease (AD). These tests have a low 
diagnostic accuracy for the detection of subcortical cognitive impairment (SCI) 
which is present in many brain diseases, such as vascular dementia, normal 
pressure hydrocephalus (NPH), Huntington’s disease, progressive supranuclear 
palsy and Parkinson’s disease5,6,7.  
 
Cerebrovascular disease is the second most common cause of acquired 
cognitive impairment and dementia and also has a contribution in cognitive 
decline in AD. The whole concept of vascular dementia has been traditionally 
based on stroke and the multi-infarct model and definitions for cognitive 
deterioration were based on criteria for AD according to the DSM-IV8. 
However, there is now agreement that cognitive impairment associated with 
cerebrovascular disease frequently does not fulfil these criteria and the term 
‘vascular cognitive impairment’ is proposed to cover individuals who have 
cognitive impairment related to stroke, multiple cortical infarcts, multiple 
subcortical infarcts, strategic infarcts or small-vessel disease9. There is a need 
for classifying these different subtypes of vascular cognitive impairment and 
refine the diagnostic criteria. Recently, clinical criteria for vascular cognitive 
impairment caused by subcortical ischaemic vascular disease (SIVD), a homo-
geneous subtype of vascular cognitive impairment, have been developed10. The 
clinical identification consists of the following features: (1) slowing of psycho-
motor functions; (2) memory deficits with relatively intact recognition; (3) 
disturbances of executive function, and (4) emotional and psychological 
changes1,10,11. Patients with NPH have an identical cognitive profile and are 
clinically difficult to differentiate from patients with SIVD11. Because of the 
frequency of SIVD as a common cause of vascular cognitive impairment, there 
is a need for a simple screening test, which has to be validated in this patient 
group. 
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Recently, a brief mental test, the ‘Human Immunodeficiency Virus (HIV) 
Dementia Scale’ (HDS), has been developed and has been shown to detect SCI 
with high accuracy in a young population with HIV infection12. The aim of this 
study was to validate the HDS in a group of elderly patients with SCI as a result 
of SIVD or NPH. 
 
 
Materials and methods 
 
The study population consisted of patients with SIVD or NPH and control 
subjects of 60 years or older. Patient selection was based on the clinical 
syndrome of SCI characterized by slowing of psychomotor functions, memory 
deficits with a relative intact recognition, executive dysfunction and mood 
abnormalities10,11. The clinical syndrome of SCI was assessed by an 
experienced neurologist and clinical identification was based on the proposed 
criteria10. Patients were included when the clinical diagnosis of SCI was 
confirmed by neuropsychological assessment. SIVD was diagnosed according 
to NINDS-AIREN criteria13. However, according to these criteria, at least 25% 
involvement of the white matter is necessary to support a clinical diagnosis of 
vascular dementia. We allowed a lesser degree of white matter changes as 
support of our clinical diagnosis of SIVD as it has been suggested recently that 
even less extensive leukoaraiosis may cause vascular cognitive impairment14. In 
this study, patients with  subcortical vascular cognitive impairment were 
defined as having a clinical and neuropsychological assessment of SCI, and 
having periventricular and deep white matter lesions or leukoaraiosis on MRI 
or CT, respectively. Nearly all patients with subcortical vascular cognitive 
impairment had a history of vascular risk factors, like hypertension, diabetes 
mellitus, atrial fibrillation, hypercholesterolaemia and peripheral artery disease, 
or a history of focal neurological deficits. Patients with an NPH were diagnosed 
by an experienced neurologist in this field as having the triad of gait disorder, 
urge incontinence and the clinical syndrome of SCI with dilated ventricles on 
MRI15. 
 
The control subjects were recruited from healthy spouses of the patients, or out-
patients without apparent cognitive problems and with normal results on 
neuropsychological testing. Patients with a depression according to the DSM-
IV criteria were excluded8. 
 
The neuropsychological test battery used as the gold standard consisted of five 
tests, all aimed at subcortical cognitive dysfunction: (1) an eight-word auditory 
verbal learning task, a subtest of the Amsterdam Dementia Scale (ADS)16; (2)  
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the fluency subtest of the Groninger Intelligence Test (a Dutch version of the 
Primary Mental Abilities Test)17, requiring the subject to name as many animals 
and professions for 1 minute each; (3) the trail-making test parts A and B18, 
which assess visuo-motor tracking and divided attention; (4) the Stroop colour 
word test parts I, II and III19, measuring speed and focused attention, and (5) 
the Wechsler Adult Intelligence Scale digit symbol test20, assessing complex 
scanning and visual tracking. Scores in the first decile were defined as 
impaired. A case was classified as SCI if less than 6 of the 8 test parameters 
were normal and at least 2 were impaired. 
 
Educational attainment was rated on an ordinal scale ranging from 1 
(incomplete primary) to 7 (university). 
 
Based on the clinical and neuropsychological diagnosis, 53 patients were 
included in our study and 54 control subjects. The underlying diagnoses in the 
patient group were 36 patients with SIVD and 17 patients with a normal 
pressure hydrocephalus. 
 
All subjects were administered the MMSE and the HDS. The HDS consists of 4 
subtests (figure 1): (1) Recall. The patient is asked to repeat and remember 4 
words. The presentation of the words is repeated until the patient can repeat all 
4. Recall is tested after 5 minutes. Spontaneously recalled words are awarded 1 
point, words remembered in response to a cue are given a half point. The 
maximum is 4 points. (2) Anti-saccadic error task modified from Currie et al.21. 
Patients are asked initially to focus on the examiner’s nose and then look to and 
fro the examiner’s moving index finger and nose. This is done with alternating 
hands, with the examiner’s hands held at the patient’s shoulder width and eye 
height. When the patient is comfortable looking at the finger that moves, he/she 
is asked to look at the index finger not moving. This task is practiced until the 
patient is familiar with the task. The patient is then asked to perform 20 serial 
anti-saccades. An error is recorded when the patient looks towards the finger 
that moved. The total number of errors out of 20 trials is coded on a scale with 
a maximum of 4 points. (3) Psychomotor speed. The time taken to write the 
entire alphabet in upper case letters with a ballpoint is recorded. Before 
performing the task, the patient is asked to recite the alphabet. Patients unable 
to do so correctly are asked to count from 1 to 26. If this succeeds, the time 
needed to write the numbers 1-26 is recorded. The time taken to complete this 
task is converted into a numerical value with a maximum of 6. (4) Construction 
speed. The time needed to draw a recognizable copy of a picture of a cube is 
recorded. Prior to the task, the examiner explains that the figure has to be 
copied as precisely and quickly as possible with a ballpoint pen. The time taken 
is converted into a numerical score with a maximum of 2. 
Chapter 2 
20 
 
Max score Score 
MEMORY-REGISTRATION 
Give four words to recall (dog, hat, green, peach)1 
1 second to say each. Then ask the patient all 4 after you 
have said them. 
4  (   ) ATTENTION 
Anti-saccadic eye movements: 20 commands. 
___ errors of 20 trials 
≤ 3 errors = 4, 4 errors = 3, 5 errors = 2, 6 errors = 1, > 6 
errors = 0. 
6  (   )  PSYCHOMOTOR SPEED 
Ask the patient to write the alphabet in upper case letters 
horizontally across the page and record the time: ___ 
seconds. 
≤ 21 seconds = 6; 21.1- 24 seconds = 5; 24.1- 27 seconds = 
4; 27.1- 30 seconds = 3; 30.1- 33 seconds = 2; 33.1- 36 
seconds = 1; >36 seconds = 0. 
4  (   ) MEMORY - RECALL 
Ask the 4 words from registration above. Give 1 point for 
each correct answer. For words not recalled prompt with a 
semantic clue, as follows: animal (dog); piece of clothing 
(hat); color (green); fruit (peach). Give ½ point for each 
correct answer after prompting.  
2  (   ) CONSTRUCTION 
Copy the cube below; record time: ___ seconds. 
<25 seconds = 2; 25- 35 seconds = 1; >35 seconds = 0, 
cube wrong=0.  
 
 
 
 
 
 
 
TOTAL SCORE: ___/ 16 
 
1In the Dutch version we used the words kat (cat), hoed (hat), geel (yellow), perzik (peach). 
 
Figure 1. The HIV dementia scale 
 
The numerical score of the different items was based on the mean performance 
scores of the first 20 HIV-seronegative patients tested in the original study11. It 
was not clear from their study how an incorrectly drawn cube was scored, but 
in our study we decided to give zero points when the patient was drawing the 
cube incorrectly. 
 
In a subgroup of the study population, the HDS assessment was repeated during 
the second and third visit by the same investigator or by an independent 
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investigator to assess the test-retest reliability and the inter-observer reliability, 
respectively. In all cases, the results of the first HDS assessment were used for 
the main analysis. 
 
Statistical analysis 
The data were analyzed using SPSS 11.0 for Windows. The t test was applied 
to test significance of differences of the demographic factors between the two 
groups and the Mann-Whitney U test was applied to test significance of 
differences of the results of the HDS between the two groups. Significance was 
accepted at the level of p<0.05 (two-sided). A receiver-operating characteristics 
(ROC) curve was generated graphically by plotting paired sensitivities and 
specificities at different cut-off values. The optimal cut-off value was 
determined. The predictive values corresponding with the optimal cut-off value 
were calculated. Inter-observer and test-retest variabilities were calculated with 
kappa statistics. 
 
 
Results 
 
Demographic characteristics are given in table 1. There were no significant 
differences between SCI patients and controls in the distribution of age, gender 
and education. The results of the HDS are shown in table 2 (see page 22). 
 
Table 1. Demographic characteristics of the SCI and the control group (mean values with 
standard deviations). 
 
Test-retest reliability was assessed in 42 consecutive SCI patients or controls 
and yielded a kappa score of 0.80, indicating good agreement. The median 
duration between visits was 17 days. 
 
Inter-observer reliability was assessed in 26 consecutive patients or controls 
and yielded a kappa score of 0.62, indicating moderate agreement. The median 
duration between the inter-observer visits was 14 days. 
Group SCI Controls SCI vs. Control
Number enrolled (N) 53 54
Age (yrs) 74.9 ± 5.9 73.9 ± 6.0 NS
Sex (% male) 53 56 NS
Education 3.6 ± 1.6  4.2 ± 1.7 NS
MMSE 26.5 ± 3.1 28.6 ± 1.4 p<0.0001
NS = Not significant
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Table 2. Instrument values of each group (mean values with standard deviations). 
 
Item results are shown in table 3. The mean raw score was on all counts signi-
ficantly lower in SCI patients than in controls. The patients with SCI failed to 
copy the cube correctly more often than the controls. 
 
Table 3. Mean raw and numerical scores with standard deviations on HDS items in the SCI 
group and in the control group. 
Because almost all control subjects had an MMSE score of 27 or higher, a sub-
analysis was performed comparing SCI patients and controls who scored in this 
range (table 2). There were no significant differences between these subgroups 
with regard to mean age, sex and education. The mean difference in MMSE 
score was significant but small (0.8 points) and clinically not relevant, whereas 
the difference in HDS score was large (6.8 points). 
 
To determine the optimal cut-off score for identifying SCI versus controls with 
the HDS, an ROC curve was constructed (figure 2). The ROC curve yielded an 
optimal cut-off value for an HDS score of 9. Based on this cut-off value, the 
sensitivity was 91% (95% CI 79-97), the specificity 96% (95% CI 87-99), the 
positive predictive value 96% (95% CI 86-99) and the negative predictive value 
91% (95% CI 81-97). 
 
 
Group SCI Controls SCI vs. Control
HDS 5.1 ± 3.5 13.0 ± 2.4 p<0.0001
Subanalysis:
MMSE score ≥ 27, n 35 50
MMSE score 28.1 ± 1.1 28.9 ± 1.0 p=0.002
HDS 6.2 ± 3.4 13.0 ± 2.4 p<0.0001
SCI Controls SCI Controls
(raw score) (raw score) (numerical score) (numerical score)
Item 1 (anti-saccadic  eye 
movements)
5.6 ± 4.2 errors 2.5 ± 2.1 errors 1.9 ± 1.8 3.5 ± 1.1
Item 2 (alphabet) 53.8 ± 31.2 s 22.2 ± 5.2 s 0.9 ± 1.7 4.9 ± 1.3
Item 3 (memory task) 1.8 ± 1.2 words 3.3 ± 0.8 words 1.7 ± 1.2 3.3 ± 0.8
Item 4 (cube copy time, rightly 
drawn)
56.2 ± 71.0 s 22.8 ± 16.5 s 0.5 ± 0.8 1.3 ± 0.9
Cube wrong, (%) 71 26      -      -
Group
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Discussion 
 
Our results show that the HDS discriminates well between patients with SCI 
and normal controls in an older population. Further, we showed that the HDS is 
of additional value in subjects whose MMSE score falls within the normal 
range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. ROC curve for HDS to determine the optimal cut-off score for 
diagnosing SCI. 
 
The HDS consists of 4 items and is easy to administer. The time needed for 
performing the items lies between the 4 and 6 minutes, depending on the 
severity of the clinical symptoms. All items of the HDS represent characteris-
tics of SCI: psychomotor speed, concentration and memory skills. Executive 
functions are evaluated to a certain degree by the anti-saccadic eye movement 
task and the cube copy task.  
 
Several screening tests for the detection of SCI have been described, but none 
is generally accepted for adaptation in general practice. The Mattis Dementia 
Rating Scale22 is mentioned frequently and seems to be sensitive to frontal and 
subcortical dysfunction. However, considering the structure of the Mattis 
Dementia Rating Scale and the time needed to perform it, it does not seem to be 
useful in clinical practice. The Frontal Assessment Battery has recently been 
designed by Dubois et al.23. It is a short cognitive and behavioural battery to 
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assess frontal lobe functions. This test has been investigated only in patients 
with frontal lobe dysfunction, like in Parkinson’s disease, multiple system 
atrophy, corticobasal degeneration, frontotemporal dementia and progressive 
supranuclear palsy. Patients with SIVD, probably one of the most important 
causes for SCI, however, were not included. The clock drawing task strongly 
associated with executive functions has been tested in control subjects versus 
patients with probable AD, but not in patients with SCI24. 
 
Patients with AD were not investigated in this study. Generally, these patients 
present with a different clinical picture and a lower score on the MMSE. 
However, patients with mild cognitive impairment (MCI) and a normal MMSE 
score may fail the HDS. It would be interesting to evaluate the HDS in patients 
with MCI with and without vascular risk factors, in order to differentiate 
between MCI and subcortical vascular cognitive impairment in patients with an 
MMSE score of 27 or more. 
 
Furthermore, studies have to be performed to validate the HDS in other dis-
eases causing SCI, like Parkinson’s disease, multiple sclerosis or Huntington’s 
disease. 
 
We deliberately chose a group of patients with SIVD as the most important 
cause of SCI in this study. Very often, these patients do not present with focal 
neurological deficits but primarily manifest with gradually deteriorating 
cognitive functions. The extent of ischaemic disease on neuroimaging that is 
both sufficient and necessary to cause cognitive impairment is yet unclear. 
Because SIVD is an important cause of cognitive decline in the elderly 
population, the HDS may be very useful as a screening test in a population with 
vascular risk factors23,25. 
 
These results suggest that the HDS is able to detect SCI in an elderly popu-
lation with SIVD or NPH and a normal MMSE score.  
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Abstract 
 
Objective: 
The event-related potential (ERP) evoked by the auditory oddball paradigm has 
been investigated mainly in patients with Alzheimer’s disease and in patients 
with different causes of subcortical dementia. Subcortical ischaemic vascular 
disease (SIVD) seems to be an important cause of vascular cognitive impair-
ment (VCI) frequently not fulfilling the criteria for dementia. Recognition of 
VCI is needed in order to provide adequate care and therapy. The aim of this 
study was to investigate the diagnostic value of the different elements of this 
response (N1, N2 complex and P3 latencies) in a group of elderly patients with 
VCI caused by SIVD. 
 
Methods: 
The study population consisted of patients with a clinical and neuropsycho-
logical diagnosis of VCI caused by SIVD (N = 38) and healthy control subjects 
(N = 53) aged 60 years or older. The mean Mini Mental State Examination 
score of both groups was 27.6 and the mean HIV Dementia Scale score was 6.1 
in the patient group and 12.3 in the control group. 
In all subjects, the ERP was recorded under standardized conditions, and the 
latencies and amplitudes of N1, N2 and P3 were analyzed by two clinical 
neurophysiologists in consensus. Both were blinded to the diagnosis. 
 
Results: 
The N2 latency was significantly longer in patients with VCI than in age-
matched controls, whereas the latencies of the P3 and N1 were not significantly 
different. The peak-to-peak amplitude of the N2 complex to the P3 wave was 
significantly lower in the patient group. White matter abnormalities on MRI 
were not significantly correlated with the N2 latency. 
 
Conclusion: 
Our findings suggest that the latency of the N2 complex is prolonged and the 
peak-to-peak amplitude of the N2 complex to P3 wave is lowered in patients 
with VCI caused by SIVD. 
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Introduction 
 
The auditory oddball paradigm is a neurophysiological method for eliciting an 
event-related potential (ERP). This multiwave response contains different 
deflections and the highest amplitude is usually measured at about 300 milli-
seconds (P3)1. The late responses elicited by the auditory oddball paradigm are 
considered to be related to cognitive processing2. The latency of the N2 
complex and the P3 is prolonged in patients with  Alzheimer’s disease,  
Parkinson’s disease, Huntington’s disease, Binswanger’s disease and  depres-
sion3,4,5,6,7. Moreover, subcortical dementia can be distinguished electrophysio-
logically from cortical dementia by changes in the latency of the early waves of 
the ERP and especially in the latency of the N1, which is delayed in subcortical 
dementia8,9. Thus, the latency of the different deflections of the ERP may be 
useful in diagnosing dementia. However, in most patients the disease is already 
advanced at diagnosis 3,4,5,6,7, whereas early diagnosis is needed in order to 
provide adequate care and therapy. 
 
Subcortical ischaemic vascular disease (SIVD) is an important cause of 
vascular dementia10. However, recently the term vascular cognitive impairment 
(VCI) has been proposed because clinically important cognitive impairments 
associated with SIVD do frequently not fulfil the criteria for dementia10. 
Criteria for dementia are traditionally based on the concept of Alzheimer’s 
disease and require the presence of prominent memory impairment which is not 
necessarily a key symptom in VCI. VCI is characterized by slowing of psycho-
motor functions and executive dysfunction10,11,12. The frequently used mini 
mental state examination (MMSE)13 as a screening tool is therefore not sensiti-
ve for the detection of VCI, whereas the recently validated HIV dementia scale 
discriminates well between patients with VCI and normal control subjects14. 
 
Only five studies have investigated the auditory oddball paradigm in patients 
with vascular white matter disease, i.e. leukoaraiosis or lacunar infarcts 
6,15,16,17,18. However, in these studies the definitions of cognitive decline were 
based on criteria for Alzheimer’s dementia according to DSM-IV19, the tests of 
cognitive function were not described in detail, and the studies were limited to 
the analysis of the P3 wave only. 
 
In this study, we aimed to determine whether the different deflections of the 
ERP (N1, N2 complex and P3) evoked by the auditory oddball paradigm could 
differentiate patients with VCI caused by SIVD in an early phase of the disease 
from age-matched controls. 
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Methods 
 
The study population consisted of outpatients living independently with VCI 
due to SIVD and healthy control subjects. All patients and control subjects 
were older than 60 years. The clinical diagnosis of VCI due to SIVD was made 
by an experienced neurologist and was based on the research criteria according 
to Erkinjuntti12. The cognitive syndrome was characterized by slowing of 
psychomotor functions, executive dysfunction, memory deficits with a relati-
vely intact recognition and mood abnormalities12. The clinical diagnosis was 
supported by neuropsychological tests performed by a qualified neuropsycho-
logist. 
 
The neuropsychological test battery consisted of five tests aimed at subcortical 
cognitive dysfunction: (i) an 8-word auditory verbal learning task, a subtest of 
the Amsterdam Dementia Scale (ADS)20; (ii) the fluency subtest of the Gronin-
gen Intelligence test (a Dutch version of the Primary Mental Abilities test)21, in 
which the subject is required to name as many animals or professions as 
possible in 1 minute each; (iii) the Trail-making test parts A and B22, which 
assess visuo-motor tracking and divided attention; (iv) the Stroop color word 
test parts I, II and III23, which measure speed and focused attention; and (v) the 
WAIS digit symbol test24, which assesses complex scanning and mental speed, 
or the Grooved Pegboard Test25 which measures motor speed. A patient was 
classified as having subcortical cognitive impairment if fewer than six of the 
eight test parameters were normal and at least two were impaired, i.e. a score in 
the lowest decile. 
 
In this study, patients with VCI were defined as having a clinical and neuropsy-
chological profile of subcortical cognitive impairment and white matter hyper-
intensities, lacunar infarctions or leukoaraiosis, i.e. SIVD on magnetic reso-
nance imaging (MRI) or computed tomography (CT). SIVD was diagnosed 
according to the NINDS-AIREN criteria26. However, according to these 
criteria, at least 25% involvement of the white matter is necessary to support a 
clinical diagnosis of vascular dementia. We allowed a lesser degree of white 
matter changes as support of our clinical diagnosis of VCI because it has been 
recently demonstrated that even less extensive leukoaraiosis may cause 
VCI10,27. All patients with VCI had a history of vascular risk factors, such as 
hypertension, diabetes mellitus, atrial fibrillation, hypercholesterolemia or peri-
pheral artery disease. The white matter hyperintensities and lacunar infarctions 
on MRI were scored according to the semi-quantitative rating scale described 
by Scheltens et al.28. This scale rates periventricular and white matter signal 
hyperintensities as well as basal ganglia and infratentorial signal hyperin-
tensities separately29. The control group consisted of healthy spouses or outpa-
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tients without cognitive problems and with normal results on neuropsycho-
logical testing. Patients as well as control subjects with a depression according 
to the DSM-IV criteria were excluded19. 
 
On the basis of the clinical, neuropsychological and radiological findings 38 
patients and 53 control subjects were included in our study. All patients and 
control subjects were evaluated with the Mini Mental State Examination 
(MMSE)13 and the HIV dementia scale (HDS)14. The HDS was chosen as a 
screening tool, because as mentioned previously the HDS is more sensitive and 
clinically more relevant for the detection of VCI than the MMSE13.  Twenty-
four patients underwent an MRI and 14 patients a CT of the brain. 
 
Recording conditions 
 
Figure 1. 
The ERP of an individual patient. The results of the replicable waves of the standard stimuli are 
seen on the left side, the results of the target stimuli on the right. The electrode positions were 
located on Fz (mid frontal), Cz (mid central) and Pz (mid parietal). The arrows signify the locations 
where the N1, N2 and P3 latencies were measured. The first 100 ms reflects the prestimulus 
interval; the arrowhead indicates the start of the stimulus. 
 
Electroencephalographic (EEG) activity was recorded at the frontal (Fz), cen-
tral (Cz) and parietal (Pz) electrode sites of the 10-20 system using Ag/AgCl 
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electrodes affixed with electrode paste, referred to linked earlobes with a fore-
head ground and impedance of 5 kΩ or less. The digitization rate was 512 Hz 
with a resolution of 8 bits. The analysis period was 1000 ms including a 100-ms 
prestimulus baseline. The recording bandpass was 0.1-50 Hz. The artifact 
rejection level was based on a signal amplitude of 200 µV. Waveforms were 
averaged by a Nihon Kohden Neuropack Minifour MEB-5304K Electromy-
ograph, which also controlled the stimulus presentation and artifact rejection. 
All experimental conditions were recorded with eyes closed and subjects 
resting comfortably on a couch. Each subject was presented with a sequence of 
100 binaural tones (80 dB SPL, 100 ms duration, including 10 ms rise and fall 
times). In 80% of the trials, the tone had a pitch of 1000 Hz (frequent tone) and 
in 20% of the trials it was at 2000 Hz (target or oddball stimulus). The 
sequence of tones was pseudorandom with the constraint that no two rare tones 
occurred consecutively. The stimulus rate was 0.5 Hz with a random occur-
rence of 20%. Subjects were instructed to listen to the tones and raise the index 
finger of one of their hands whenever the target tone was detected to ensure 
optimal attention. A total of 20 artifact-free reponses to standard or target 
stimuli were averaged at each location. The procedure was recorded twice for 
reproducibility. A typical wave form of a patient is shown in figure 1 (see page 
31). The average ERPs were analyzed by two clinical neurophysiologists 
blinded to the diagnosis of the patient. The latency of the N1 was measured 
from the standard tone wave and identified as the largest negative peak within 
the 70- to 150-ms range derived from the Cz electrode. The latency of the N2 
complex was measured from the target wave as the largest negative peak within 
150-320 ms derived from the Cz electrode. The P3 was the largest positive 
peak around the 300 ms within a range of 250-600 ms and was measured from 
the Pz derivation of the target wave.  If a bifurcated P300 was present, the top 
P3b was chosen for analysis2. The amplitudes of the P2-to-N2 peak and of the 
N2-to-P3 peak were measured from the Cz derivation of the target wave. 
 
Statistical analysis 
The data were analyzed using SPSS 11.0 for Windows (SPSS, Chicago, Ill., 
USA, 2001). Data are reported as means with standard deviation. The two-
tailed Student t test was applied to test for differences in age between group 
means. The Pearson χ2 test was applied to test for differences in sex. The 
Mann-Whitney U test was used to test for differences in the MMSE and HDS 
scores and to compute differences in amplitudes. Differences in latencies were 
tested with the general linear model with patient group as fixed factor and age 
and sex as covariates. Correlations between the different latencies of the ERP 
and signal hyperintensities on MRI or scores on the neuropsychological tests 
were computed with Spearman’s correlation coefficient. Significance was ac-
cepted at the level of p<0.05 (two-sided). 
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Results 
 
Table 1. Mean values with standard deviations of the demographic characteristics in patient 
group (VCI) and controls 
Baseline characteristics are given in table 1. The patients and control subjects 
differed significantly in mean HDS score and in sex distribution, but not in age 
or mean scores of the MMSE. The latency of N2 complex was significantly 
longer in the patient group than in the control group (p=0.001, 95% CI of 
difference of means 9.7- 34.7; table 2). N2 was not detected in 2 (5.3%) 
patients and in 4 (7.5%) control subjects. The mean latencies of the N1 and the 
P3 waves did not differ significantly between the patient group and the control 
group (p= 0.66 and p= 0.12, respectively). The N1 wave was not detected in 1 
patient (2.6%) and in 2 control subjects (3.8%), and the P3 wave was not 
detected in 6 patients (15.8%) and in 6 control subjects (11.3%). The demogra-
phic variables and the neuropsychological scores of patients without an N1, N2 
or P3 wave were not significantly different from those of the patients with 
detectable waves. 
 
Table 2. Results of the different waves of the auditory oddball paradigm in the patient group 
(VCI) and control group 
 
The peak-to-peak amplitude of the N2 wave to the P3 wave was statistically 
significantly lower in the patient group (table 3, see page 34). 
VCI (n=38) Controls (n=53) p-value
Sexe, m/f 15/23 33/20 0.031 
Age, years 75.2 ± 6.9 73.6 ± 6.0 NS2
MMSE 27.6 ± 1.6 27.8 ± 2.4 NS3
HDS  6.1 ± 3.7 12.3 ± 3.1 <0.0013
3 Mann-Whitney U test
MMSE: Mini Mental State Examination
HDS : HIV Dementia Scale, a screening test for subcortical cognitive impairment
1 Pearson χ2 test
2 Student t test
VCI (n=38) Controls (n=53) p-value 95% CI of difference 
of means
N100 (ms) 101.5 ± 14.3 100.8 ± 10.3 0.66 -4.3 to 6.7
N200 (ms) 254.6 ± 25.1 232.5 ± 28.6 0.001 9.7 to 34.7
P300 (ms) 413.8 ± 57.3 394.4 ± 49.2 0.12 -5.5 to 44.5
Data are mean values of the latencies in milliseconds with standard deviations. The general linear model 
was applied to test for differences in latencies between both groups. For p values and confidence intervals 
(CI), means were adjusted for age and sex.
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The severity of white matter hyperintensities were assessed according to the 
Scheltens’ rating scale only in patients who underwent MRI (n=24)28. The 
mean Scheltens’ score was 10.5 ± 6.7 (range 2-24). The N2 latency was not sig-
nificantly correlated with the Scheltens’ total score (ρ = -0.255; p = 0.3) or with 
Scheltens’ sub-scores for deep white matter hyperintensities and periventricular 
hyperintensities. Also the presence of lacunar infarcts on MRI was not corre-
lated with the N2 latency. However, the N2 latency was significantly correlated 
with the total neuropsychological score (ρ = -0.310; p = 0.004), while the P3 
was not. 
 
Table 3. Results of the peak-to-peak amplitudes of the auditory oddball paradigm in the patient 
group (VCI) and control group. 
 
 
Discussion 
 
We found the latency of the N2 complex to be significantly different in a well-
defined group of patients with VCI and age-matched controls, while this was 
not the case for the latency of the N1 and P3 wave. Also the peak-to-peak am-
plitude of the N2 complex to the P3 wave was statistically significantly 
diminished in the patient group. Usually the latencies of both the N2 complex 
and the P3 waves are prolonged in demented patients, regardless of the under-
lying pathology8. However, in contrast to other study populations, our patients 
had cognitive impairment but not clinical dementia demonstrated by MMSE 
scores within the normal range and HDS scores outside the normal range14. 
This finding is consistent with the results of Cicconetti et al.29, who found that 
the N2 latency, but not the P3 latency, was significantly prolonged in a group 
of elderly hypertensive patients with an MMSE score of 27 or higher. Although 
MRI or CT of the brain was not performed in that study, it is conceivable that 
the patients had some form of mild cognitive impairment, due to vascular white 
matter abnormalities caused by hypertension, which is a major risk factor for 
SIVD30. However, a significant positive correlation could not be demonstrated 
in the present study between the severity of white matter abnormalities, the 
presence of lacunar infarctions and the N2 latency in a subgroup of our study 
population who underwent MRI. This may be explained by the small sample 
size, but tentatively it could suggest that the difference in N2 complex between 
VCI (n=38) Controls (n=53) p-value (Mann Whitney 
U test)
P2N2 (μV) 11.42 ± 6.6 11.09 ± 5.9 0.92
N2P3 (μV) 11.47 ± 7.0 15.44 ± 9.4 0.02
Data are mean values of the amplitudes in microvolts (μV) with standard deviations.
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groups is not caused by the changes identified on MRI but by unknown factors. 
The lack of correlation is not completely surprising since the clinical impact of 
the severity of WML on cognition is also under discussion31,32. However, we 
did find a significant correlation between the N2 latency and the total neuropsy-
chological score, while this was not the case with P3. This supports the clinical 
value of our finding.  
 
A prolonged N2 latency with a normal P3 latency supports the idea that the N2 
and P3 components are generated separately and not in orderly sequence33. 
Indirect evidence of a different possible subcortical generator of the N2 could 
be inferred by a delayed P3 component while the N2 was not altered after 
cortical inhibition by low-frequency transcranial magnetic stimulation34.  
 
A diminished peak-to-peak amplitude from the N2 complex to P3 was found in 
the patient group with VCI of the present study. While measuring peak-to-peak 
amplitude it is not clear if this is due to either a diminished N2 amplitude or a 
diminished P3 amplitude. Another option is that both amplitudes are dimini-
shed. However, latency is a much more reliable indicator than amplitude, since 
latency is difficult to alter with attention35. Moreover, it is known that ampli-
tudes have a large variance even within several measurements in the same 
patient, as these amplitudes depend on a high number of parameters, such as 
electrode position or impedance8,36. Even data from a normative ERP aging 
study show larger coefficients of variation for amplitudes than for peak 
latency37. 
 
We did not include patients with Alzheimer’s disease in our study. Although 
Goodin and Aminoff9 reported that the N1 latency is prolonged in subcortical 
dementia compared with cortical dementia, we did not find a prolonged N1 
wave in our patients compared with the controls. However, the study of Goodin 
and Aminoff9 included patients with Huntington’s disease or Parkinson’s 
disease but not patients with VCI9. Moreover, their patients had advanced 
disease whereas the patients in our study were clinically characterized by 
subcortical cognitive impairment and not dementia. Therefore, it would be 
interesting to compare the ERP evoked by the auditory oddball paradigm in 
patients with early Alzheimer’s disease with that in patients with VCI. 
 
In conclusion, the latency of the N2 complex is longer and the peak-to-peak 
amplitude of the N2-to-P3 wave is lower in a well-defined group of patients 
with VCI compared to healthy controls. Further research is needed to clarify the 
pathophysiological mechanism underlying the prolonged latency of the N2 
complex in patients with VCI and to compare the ERP responses of patients 
with early Alzheimer’s disease and patients with VCI.  
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Abstract 
 
Background: 
Diabetes mellitus is associated with impaired cognitive functioning and 
dementia. Brain imaging studies can provide clues on the pathogenesis, but the 
nature and severity of imaging abnormalities that are associated with diabetes 
are debated. We performed a systematic review of studies addressing this 
association. 
 
Methods: 
Eligible studies were evaluated against predefined inclusion criteria: i.e. clear 
imaging outcome measures, a clear definition of diabetes and a sample size of 
at least 20 patients. From 55 included articles data on study design, diabetes 
type, treatment and associated co-morbidity, imaging modality (MRI, MRS, 
CT, SPECT or PET) and imaging findings were extracted. 
 
Results: 
Methodology regarding population selection, diabetes assessment, neuro-
imaging rating methods and data analyses were heterogeneous. Diabetes was 
associated with cerebral atrophy in 8 out of 10 studies reporting this outcome. 
Eight out of 19 studies reported an association between diabetes and lacunar 
infarcts. There was little evidence for an association with white matter lesions. 
PET and SPECT studies reported regional abnormalities of cerebral blood flow 
and cerebral glucose metabolism. None of the studies assessed the relation 
between imaging findings and cognition. Data on the relation between imaging 
findings and disease variables (e.g. age, hypertension, medication use, 
glycaemic control) were scarce.  
 
Conclusions: 
Diabetes is associated with cerebral atrophy and lacunar infarcts. The asso-
ciation with white matter lesions is equivocal. High quality prospective studies 
are needed, with objective, sensitive and quantitative neuroimaging rating 
methods and assessment of cognition, vascular disease and other co-morbidity. 
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Introduction 
 
Diabetes Mellitus (DM) is associated with impaired cognitive functioning and 
an increased risk of dementia1,2. Patients with type 1 DM (DM1) may show 
mild to moderate slowing of mental speed and diminished mental flexibility, 
whereas learning and memory are relatively spared3. In patients with type 2 
DM (DM2) cognitive impairment may be relatively more pronounced, parti-
cularly affecting verbal memory or complex information processing4,5. The 
pathogenesis is still uncertain, but chronic hyperglycaemia, vascular disease, 
repeated hypoglycaemic episodes, and possibly direct effects of insulin on the 
brain have been implicated6. Brain imaging studies can help to clarify the 
pathogenesis. An increasing number of studies report both focal vascular and 
more global (e.g. atrophy) cerebral changes, but the results are not always 
consistent. 
 
Our aim was to systematically review brain imaging studies in patients with 
DM. Data on the relation of imaging with cognition and with relevant disease 
variables were also recorded. 
 
 
Methods 
 
Study Selection 
MEDLINE and EMBASE (1966 to February 2006) were searched with the 
following medical subject heading (MeSH) terms and textwords: computed 
tomography (CT) and magnetic resonance imaging (MRI) studies: white 
matter, leukoaraiosis, lacunar infarction, subcortical, periventricular, brain, 
cerebral, hippocampus, atrophy, MRI, magnetic resonance imaging, CT, 
tomography; magnetic resonance spectroscopy (MRS) studies: magnetic 
resonance spectroscopy, MRS, brain, cerebral; positron emission tomography 
(PET), single photon emission CT (SPECT) and Xenon-enhanced CT studies: 
cerebral blood flow, glucose metabolism, brain, cerebral, PET, SPECT, Xenon, 
positron emission tomography, single-photon emission tomography, 
tomography; all combined with “diabetes”. 
 
The abstracts were screened and potentially relevant articles retrieved.  These 
articles were included if they met the following four criteria. 1) original article, 
written in English, on brain imaging in adult patients with DM in comparison 
with controls, 2) diagnostic criteria for DM specified, 3) sample size of at least 
20 DM patients, or a total sample size > 200 if the number of DM patients was 
not specified, 4) for CT or MRI studies: specification of the rating method for 
WML, or atrophy. Eligible articles were evaluated against the inclusion criteria 
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by two independent authors (BvH, FEdL or GJB). In case of disagreement a 
consensus meeting was held. If multiple articles reported on the same imaging 
outcome measure from the same study population, the article with the most 
detailed data on brain imaging and/or the largest study population was 
included. 
 
The search strategy for MRI and CT studies yielded 271 articles. Three addi-
tional articles were identified through bibliographies of included articles7-9. 
After screening of title and abstracts, 117 were retrieved full-text, of which 46 
were included. The search for MRS studies yielded 75 articles, of which 3 were 
included. The search strategy for PET, SPECT and Xenon-CT yielded 84 
articles, of which 6 were included. 
 
From included studies the source population (e.g. population or clinic based), 
experimental design (e.g. cross-sectional, longitudinal), sample size, and age of 
the participants were recorded. The procedure for diagnosing DM was recorded 
(e.g. based on history, based on oral glucose tolerance test) as well as the DM 
type of the population involved (DM1, DM2, mixed or unknown). If the DM 
type was not specified and the mean age of the patients was 60 years or higher, 
the population was classified as “predominantly DM2”. The imaging modality 
and the methods to rate WML, atrophy, lacunar infarcts, cerebral blood flow 
(CBF) or cerebral glucose metabolism were recorded. Effect sizes (Cohen’s d), 
odds ratios (OR) or relative risks (RR) with 95% confidence intervals (CI) for 
these outcome measures were recorded or calculated based on the available 
data. Data on the relation between relevant co-morbidity (e.g. hypertension) 
and DM related variables (e.g. glycaemic control, microvascular complications, 
DM duration, medication use) and the imaging outcome measures were also 
recorded. 
 
The source of the study populations in CT or MRI studies varied considerably, 
from true population-based sampling to populations with vascular or cognitive 
pathology. To improve clarity we therefore classified the 46 included articles 
into three main categories: 1) “general cohorts” (n=11): this category included 
articles on population-based studies or case-control studies, in which the cases 
were recruited from the general population or a DM clinic; 2) ”vascular co-
horts” (n=23): this category included articles on studies that primarily recruited 
patients with stroke or other cardiovascular risk factors, and assessed the effects 
of DM within these selected populations ; 3) “outpatient cohorts” (n=12): this 
category included articles on cohorts of neurological or psychiatric outpatients, 
for example with cognitive complaints or other neurological or psychiatric 
conditions, and assessed the effects of DM within these selected populations. 
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Meta-analyses were performed on dichotomous outcome measures if a given 
outcome measure was available from at least two independent studies on the 
same cohort type with the same imaging modality (CT or MRI) and if the 
required data could be extracted from the articles. Analyses were performed 
with Review Manager Version 4.2 (Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2003) on unadjusted data. For individual studies 
no systematic differences were observed between these unadjusted ORs and 
adjusted ORs as presented in tables 1 and 2 (see page 44/45 and 46/47). 
 
 
Results 
 
CT and MRI studies 
Diabetes mellitus and WML (table 1) 
The majority of the studies used ordinal rating scales with 3 to 4 levels, ranging 
from absent to severe, confluent WML. Other studies made a dichotomization 
into presence or absence of WML. Five studies used an ordinal scale that inclu-
ded 9 or more grades of WML severity7,10,11 or an interval scale12,13. Only 3 
studies used actual volumetric measurements9,14,15. From the 7 studies catego-
rized as “general cohorts”, one observed a significant association between DM 
and WML although the actual median total deep WML volume in the DM 
group was small (<0.1 ml) 16. From the 11 studies categorized as “vascular 
cohorts”  3 reported an increased severity of WML in patients with DM 17-19. 
From the 9 studies categorized as “outpatient cohorts” only one study reported 
a statistically significant association between DM and WML20, although in 4 
studies WML scores tended to be higher in the DM group21-24. Nine of the 27 
WML studies could be included in the meta-analysis (table 4, see page 50). In 
the “vascular cohorts” there was no association between DM and WML (OR 
1.1 (95% CI 0.9-1.4)). In contrast, in the “outpatient cohorts” there appeared to 
be a modest association between WML and DM (point estimates for ORs 
varied from 1.8 to 2.4; table 4). 
 
Diabetes Mellitus and lacunar infarctions (table 2) 
Twenty articles on lacunar infarcts were included, dealing with 19 study 
populations. For one population both cross-sectional8 and longitudinal25 analy-
ses were reported. Both articles were included, but only the cross-sectional data 
are presented in Table 2 and included in the meta-analysis.  
The majority of studies used MRI. The definition of lacunar infarcts (i.e. focal 
hyperintensities on T2-weighted images with corresponding hypointense 
lesions on T1 or FLAIR imaging) was consistent across the studies. 
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Table 1. Relation diabetes mellitus and white matter lesions
No S tu dy popu lation * S u bje cts  
total /DM
Me an  age  
(yrs)
DM type Im agin g
Dejgaard 19911 6 Case/cont rol 60/20 40 1 MRI
Yousem 19913 7 Case/cont rol 35/25 31 1 MRI
Longst reth 19967 P opulat ion-based 3301/369 >65 2¶ MRI
Den Heijer 20031 2 P opulat ion-based 506/41 >60 2¶ MRI
Schmidt  20041 3 P opulat ion-based 1252/114 69 2¶ MRI
Jerekathil 20049 P opulat ion-based 1814/91 54 ND MRI
Jorm 20051 5 P opulat ion-based 475/? >60 2¶ MRI
Hijdra 19901 9 St roke 376/59 >65 2¶ CT
Schmidt  19921 7 St roke/vascular risk factors and cont rol 234/38 55 ND MRI
Manolio 19941 0 St roke and cont rol 303/76 >65 2¶ MRI
Fukuda 199563 Hypert ension 238/52 >40 ND MRI
Jorgensen 199564 St roke or T IA 1084/203 >70 2¶ CT
Awada 199639 St roke 398/131 >60 2¶ CT
Henon 199665 St roke 610/83 64 2¶ CT
P adovani 199734 St roke and cont rol 100/20 >60 2¶ MRI
Coskun 20033 8 St roke 288/57 >65 2¶ CT
Streifler 20031 8 St roke 596/110 >60 2¶ CT
Kario 20054 7 Hypert ension 20/20 69 2 MRI
Raiha 19934 1 Geriat ric department 204/55 74 2¶ CT
Araki 19942 1 MRI for any indicat ion 2725/159 60 2¶ MRI
Fukuda 199666 Neurologically normal 253/50 66 2¶ MRI
Kobayashi 19972 2 Neurologically normal 933/66 58 ND MRI
Hogervorst  20022 4 Alzheimer’s disease and cont rols 414/29 74 2¶ CT
Masana 20032 3 Mild headache and vert igo 1674/87 51 ND MRI
Lazarus 20052 0 Memory clinic 177/20 >65 2¶ MRI
T aylor 200514 Depressive disorder and cont rols 399/34 70 2¶ MRI
347/29 73 2¶ MRI
Ge n e ral  coh orts:
Vascu lar coh orts:
O u tpati e n t coh orts:
Biessels 20051 1 Memory clinic 
* Study populations: general cohorts: population-based or case-control studies; vascular cohorts: cohort with stroke or other 
cardiovascular risk factors; outpatient cohorts: neurological outpatients. 
† Rating scales: Dich: dichotomous scale; Ord: ordinal scale; Int: interval scale; **: dichotomization was performed for 
analysis.
‡ Outcome and results in DM patients compared with controls. WML = white matter lesions, DWML = deep white matter 
lesions, PVH = periventricular hyperintensities, GML = grey matter lesions, BG = basal ganglia. Odds ratio’s (OR) are 
presented with 95% CI within brackets. װ where possible, we calculated OR or effect sizes (d) if they were not provided in the 
original paper. r = Pearson correlation coefficient. Mean differences (mean diff, with 95% CI within brackets), d, β and t 
values > 0 reflect more severe WML in the DM group relative to controls. Studies marked with # were included in the meta-
analysis presented in table 4.
DM type: 2¶: population classified as predominantly DM2, see methods. ND = not determined
p-value: NS = not significant, ? = not specified
§Adjustments/matching: Edu: education; BP: blood pressure (including hypertension, mean arterial pressure, systolic blood 
pressure, use of antihypertensive drugs, left ventricular hypertrophy, ankle-to-arm index); HL: hyperlipidemia; AF: atrial 
fibrillation; PVD: peripheral vascular disease (including peripheral artery disease, coronary artery disease, cardiac disease, 
congestive heart failure, ECG changes); ICD: ischaemic cerebrovascular disease (including TIA, stroke, leukoaraiosis, white 
matter lesions, ultrasound examination of carotids or intracranial arteries) 
Studies are listed in chronological order
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Table 1. Continued 
 
Four studies were categorized as “general cohorts”8,13,25,26. Two of these studies 
reported an association between DM and symptomatic infarcts, but no asso-
ciation with silent lacunar infarcts8,26. The only longitudinal study observed an 
association between DM and silent incidental lacunar infarcts (OR 2.9 (95% CI 
1.0-8.5)) without a significant association between DM and silent infarcts at 
baseline (OR 1.9 (95% CI 0.4-4.8))25. 
 
Of the 12 studies categorized as “vascular cohorts” one showed a significant 
association between DM and silent lacunar infarcts27 and 4 between DM and 
symptomatic lacunar infarcts28-31. Of the 4 studies categorized as “outpatient 
cohorts” one showed a significant association between DM and silent lacunar 
infarcts22. 
Rating scale† Outcome and results‡ p-value Adjustments/matching§
Dich OR 15.4 (3.8 - 63.2)װ <0.05 Age
Dich No WML in either group NS Age, sex
Ord (0-9) NS Age, sex
Ord (0-9) PVH PVH: difference +0.4 (-0.2 to 1.1), d = 0.4װ NS Age, sex
Int WML WML: difference +0.01 ml (-1.0 to 1.0), d = 0.2װ NS
Int PVH: median diff 0 0.1 Sex, age, edu, BP, smoking, BMI, HL, PVD
WML: median diff +0.2 0.2
Volumetry WML: β = 0.02 0.8 Age, sex
Volumetry WML: r = 0.03 NS No
Ord (0-4)** OR 2.0 (1.1 - 3.5)װ# 0.02 No
Ord (0-3) β = 0.2 (SE 0.1) <0.001 Age, BP, sex, ICD, PVD
Ord (0-8) DM mean diff 0.4 0.1 No
Ord (0-5) DM mean diff 0.1, d = 0.2װ 0.3 No
Dich OR 0.8 (0.5 - 2.3)װ# 0.3 No
Dich OR 0.9 (0.6 - 1.5)װ# No
Ord (0-3) estimated coefficient 1.2, (SE 0.8) 0.1 Age, sex, BP, alcohol, HL, ICD, cerebral atrophy
Ord (0-3) β=0.02, SEB 0.1 0.9 age, sex, BP, PVD, ICD, ventricular index
Ord (0-4)** OR 0.6 (0.06 - 0.3)װ# NS No
Ord** OR 1.6 (1.0 - 2.6)װ# 0.04 No
Ord** OR 2.2 (0.5 - 9.0) NS age, sex, BP
Dich OR 0.9 (0.5 - 1.7)װ NS No
Dich OR 1.4 (0.7 - 2.8)װ# NS No
Ord (0-4) d = 0.1װ 0.6 Age, sex, BP, smoking, HL, ICD
Ord (PVH: 0-4)** PVH: OR 2.0 (0.8 - 4.8)װ# 0.2 No
Dich (WML) DWML: OR 0.8 (0.3 - 2.8)װ# 0.6
Ord (0-3)** OR 1.4 (0.5 - 4.3) 0.5 Age, sex, diagnosis, smoking, DM, BP, Apo E4 
Ord (0-3) OR 1.6 (0.8 - 3.0)# 0.2 Age, sex, BP, HL, family history, smoking, alcohol, ICD
Ord (0-6) PVH: mean diff 0 (-0.5 to 0.5) NS
Ord (0-24) DWML: mean diff -0.5 (-2.0 to 1.5) NS
Ord (0-4)** PVH: OR 1.6 (0.6 - 5.2)# NS Age, BP, AF, ICD
DWML: OR 2.9 (1.0 - 7.8) ?
Volumetry WML: t =-1.3 0.2 Age, sex, BP 
GML in BG: t =-1.08 0.3
Age, sex
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Table 2. Relation diabetes mellitus and lacunar infarcts 
 
We calculated the power for each study to detect statistically significant diffe-
rences between DM and non-DM subjects, assuming a relative risk of 2.0 for 
infarcts in the DM group. Despite the rather high contrast between the groups 
in this assumption, the estimated power of the majority of studies was around 
0.5, while it is common to require a power between 0.8 and 0.9. 
 
All studies on lacunar infarcts could be included in the meta-analysis (table 4). 
There was a significant association between DM and lacunar infarcts in all  
No S tu dy popu lation * S u bje cts  
total /DM
Me an  age  
(yrs)
DM type Im agin g
Longst reth 19982 6 P opulat ion-based 3660/519 >65 2¶ MRI
Vermeer 20028 P opulat ion-based 1077/75 >60 2¶ MRI
Schmidt  200413 P opulat ion-based 1252/114 69 2¶ MRI
Jorgensen 199440 St roke 494/79 >70 2¶ CT
Konemori 199567 St roke and cont rol 324/36 >50 ND MRI
Hsu 19972 8 St roke and cont rol 132/20 >60 2¶ CT
Adachi 200242 St roke 171/50 69 2¶ MRI
Revilla 200229 Lacunar infarct s and cont rol 164/28 65 2¶ CT /MRI
Arauz 200327 Lacunar infarct s 175/72 64 2¶ MRI
Selvet ella 200343 Hypertension 195/40 >60 2¶ MRI
Giele 20046 8 Atherosclerot ic vascular disease or risk factors 308/59 58 ND MRI
Karapanayiot ides 200430 St roke 4064/611 67 2¶ MRI
Sarkar 200431 St roke 450/171 51 ND CT
Kario 200547 Hypertension 20/20 69 2 MRI
Kawamoto 200544 St roke 453/40 76 2¶ CT
Araki 199421 MRI for any indicat ion 2725/159 60 2¶ MRI
Kobayashi 19972 2 Neurologically normal 933/66 58 ND MRI
Uehara 19996 9 Neurologically normal 219/37 63 2¶ MRI
Biessels 20051 1 Memory clinic 347/29 73 2¶ MRI
Ge n e ral  coh orts:
O u tpati e n t coh orts:
Vascu lar coh orts:
††For each study the power (1-β) t o det ect  a st at ist ically significant  difference between the DM and the cont rol group was est imated, 
assuming an OR for infarct s of 2.0 in t he diabet ic group and an α=0.05 with two-sided test ing 
(ht tp://calculators.st at .ucla.edu/powercalc/)
p-value: NS = not  significant
Studies are list ed in chronological order
* Study populat ions: general cohort s: populat ion-based or case-cont rol studies; vascular cohort s: cohort  with st roke or other 
cardiovascular risk factors; outpat ient  cohorts: neurological outpat ient s. 
DM type: 2¶: populat ion classified as predominant ly DM2, see methods. ND = not  determined
‡ Outcome and result s: LI = lacunar infarct s, BG =  basal ganglia. Odds rat io’s (OR) are presented with 95% CI within bracket s. װ 
where possible we calculat ed ORs if t hey were not  provided in the original paper.
§Adjustments/matching: Edu: educat ion; BP : blood pressure (including hypertension, mean art erial pressure, systolic blood pressure, 
use of ant ihypertensive drugs, left  vent ricular hypert rophy, ankle-to-arm index); HL: hyperlipidemia; AF: at rial fibrillat ion; P VD: 
peripheral vascular disease (including peripheral art ery disease, coronary art ery disease, cardiac disease, congest ive heart  failure, ECG 
changes); ICD: ischaemic cerebrovascular disease (including T IA, st roke, leukoaraiosis, white mat t er lesions, ult rasound examinat ion 
of carot ids or int racranial art eries) 
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Table 2. Continued 
cohort types (general cohorts OR 1.3 (95% CI 1.1-1.6); vascular cohorts 2.2 
(95% CI 1.9-2.5); outpatient cohorts 1.4 (95% CI 1.1-1.8)) 
 
Diabetes Mellitus and cerebral atrophy (table 3, see page 48/49) 
Ten studies addressed the relation between DM and atrophy, with marked 
heterogeneity in the methods for atrophy assessment. Some studies measured 
only cortical atrophy or hippocampal atrophy12,21,32,33, others mea-sured only 
subcortical atrophy34, while others assessed both10,11,13,35,36. 
 
All 4 studies categorized as “general cohorts” 12,13,33,36, one of the 2 studies 
categorized as “vascular cohorts” 10 and all 4 studies belonging to the “outpa-
tient’s cohorts” 11,21,32,35 showed associations between DM and cerebral atrophy, 
i.e. amygdalar atrophy, cortical atrophy or subcortical atrophy. 
The outcome measures on atrophy were too heterogeneous to perform a meta-
analysis. 
 
Relation of CT and MRI findings to cognition and other disease variables. 
Only 3 studies compared cognition between DM and non-DM patients11,16,36. 
One study, classified as a “general cohort” showed modest impairments of cog-
nitive performance in DM1-patients36, whereas a study classified as a “vascular  
Outcome and results‡ p-value Adjustments/matching§ Estimated 
power††
Silent: OR 1.1 (0.8-1.5) 0.6 Age, sex, BP, HL, smoking,  PVD, creatinine 1.0
Symptomatic: OR 2.2 (1.1-4.5)  0.02
Silent: OR 0.7 (0.4-1.5) NS Age, sex, BP, smoking 0.8
Symptomatic: OR 2.5 (1.0-5.9) <0.05
Silent: OR 1.4 (0.7-2.7)װ  0.3 Sex, age, edu, BP, smoking, BMI, HL, PVD 0.6
Silent: OR 1.4 (0.9-2.4)װ 0.2 No 0.8
Silent: OR 0.8 NS Age, sex, BP, HL 0.5
Symptomatic: OR 2.5 NS
Symptomatic: OR 12.5 (3.1-57.6) <0.05 No 0.3
Silent: OR 1.9 (0.9-3.9) 0.1 No 0.5
Symptomatic: OR 5.4 (1.5-18.9) 0.008 Age, sex, BP, HL, smoking, 0.4
Silent: OR 3.0 (1.3-7.0)   0.03 Age, sex, BP, HL, smoking, alcohol, PVD 0.5
Silent: OR 2.0 (0.9-4.1)װ 0.07 No 0.5
Silent: OR 1.4 (0.7-2.8)װ 0.4 No 0.5
Symptomatic: OR 1.8 (1.3-3.8) 0.009 Sex, smoking, HL 1.0
Symptomatic: OR 2.6 (1.8-3.9) <0.05 No 0.9
Silent and symptomatic: OR 2.3 (0.6-8.0) NS Age, sex, BP 0.2
Symptomatic: OR 0.7 (0.3-1.6) 0.35 Age, sex, smoking 0.5
Silent: OR = 1.0 (0.7-1.4)װ NS No 1.0
Silent: OR 2.4 (1.2-4.9) 0.01 Age, sex, BP, alcohol,, PVD 0.5
Silent LI white matter: OR 2.3 (0.98-5.6) 0.06 Age, sex, BP, HL, smoking, PVD
Silent LI in BG: OR 0.7 (0.2-2.1) 0.6
Silent: OR 2.3 (0.9-5.6) NS Age, sex 0.3
0.5
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Table 3. Relation diabetes mellitus and cerebral atrophy 
cohort”16 and a study of patients attending a memory clinic reported no diffe-
rence between DM and non-DM patients11. None of these studies presented 
analyses on the association between cognition and MRI findings in the DM 
population. 
 
From the 46 articles 3 study populations included only DM1 patients, 2 only 
DM2, 32 study populations were classified as “predominantly DM2” and 9 
study populations were classified as “DM of unknown type” (tables 1-3). The 
diagnosis of DM was based on history or medication use in 20 stu-
dies7,8,14,18,20,21,24,24,26,28,31-33,37-44, while in the other studies active screening was 
done by fasting glucose levels, random glucose levels or an oral glucose 
tolerance test. Only 2 studies included data on metabolic control16,36. Two 
studies on DM2 patients specified which glucose lowering therapy was 
used11,27. The duration of DM was mentioned in 2 studies16,36. 
DM type: 2¶: populat ion classified as predominant ly DM2, see methods. ND = not  determined
p-value: NS= not  significant , ? = not  specified
§Adjustment s/matching: Edu: educat ion; BP : blood pressure (including hypertension, mean art erial pressure, systolic blood pressure, use of 
ant ihypertensive drugs, left  vent ricular hypert rophy, ankle-to-arm index); HL: hyperlipidemia; AF: at rial fibrillat ion; P VD: peripheral 
vascular disease (including peripheral art ery  disease, coronary artery disease, cardiac disease, congest ive heart  failure, ECG changes); ICD: 
ischaemic cerebrovascular disease (including T IA, st roke, leukoaraiosis, whit e mat ter lesions, ult rasound examinat ion of carot ids or 
in t racranial art eries) 
* Study populat ions: general cohort s: populat ion-based or case-cont rol studies; vascular cohort s: cohort  with st roke or other 
cardiovascular risk factors; outpat ient  cohort s: neurological outpat ient s. 
Studies are listed in chronological order
†Rat ing scales: Dich: dichotomous scale; Ord: ordinal scale; Int : int erval scale
‡Outcome and result s. Odds rat io’s (OR) are presented with 95% CI within brackets. װ where possible we calculat ed ORs or effect  sizes (d 
) if t hey were not  provided in the original paper. Mean differences (mean diff; with 95% CI within bracket s), d, β  and t  values > 0 reflect  
more severe at rophy in the DM group relat ive to cont rols. 
No Study population* Subjects 
total/DM
Mean age 
(years)
DM type Imaging Rating scale† 
Longstreth 200033 Population-based 3253 /? >65 2¶ MRI Ord (0 - 9)
Den Heijer 200312 Population-based 506/41 >60 2¶ MRI Int
Schmidt 200413 Population-based 1252/114 69 2¶ MRI Ord (0 - 15)
ventricle-to-brain ratio
Musen 200636 Case-control 118/82 33 1 MRI volumetry
Manolio 199410 Stroke and control 303/76 >65 2¶ MRI Ord (0 - 9)
Padovani 199734 Stroke and control 100/20 >60 2¶ MRI Int
Pirtt ila 199232 CT for any indication 416/46 >15 ND CT Dich 
Soininen 199235 Elderly volunteers 84/25 >70 2 CT Int
 
Araki 199421 MRI for any indication 2725/159 60 2¶ MRI Dich
Biessels 200511 Memory clinic 347/29 73 2¶ MRI Ord
General cohorts:
O utpatient cohorts:
Vascular cohorts:
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Table 3. Continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Few studies presented detailed data on relevant disease variables in relation to 
brain imaging. One study indicated that higher levels of glycosylated haemo-
globin, longer duration of DM1, severe hypoglycaemic events and severity of 
retinopathy were associated with cortical and/or subcortical gray matter 
atrophy36. Although several studies collected data on for example hypertension 
and vascular morbidity (see tables 1 to 3), these data were generally only 
entered as co-variates in the analysis of the between group difference of the 
population with and without DM. Data on the effects of these variables on 
lesion severity within the DM population were not provided. 
 
MRS studies 
Three studies examined cerebral metabolism in DM with 1H-MRS. One study, 
which included 6 DM1 and 24 DM2 patients reported increased myo-inositol-
to-creatine ratios in the gray and white matter, but did not observe significant 
changes in N-acetylaspartate ratios45. Another study that included 17 DM1 (of 
which 9 were recovering from diabetic ketoacidosis) and 4 DM2 patients 
reported increased myo-inositol-to-creatine ratios and decreased N-acetyl-
aspartate-to-creatine ratios46. The third study only included DM2 patients with 
hypertension and hypertensive controls, and also showed decreased N-acetyl-
aspartate-to-creatine ratios47. The latter is regarded as an indicator of reduced 
neuronal viability48. 
Outcome and results‡ p-value Adjustments/matching§
Increase in cortical atrophy grade: ? Age, race, edu, BP, PVD, alcohol
Men: 0.6 (0.2-0.9) Women: 0.2 (0 - 0.4) 
Hippocampal volume: -4% (0 - 9)  ʻ 0.04
Amygdalar volume: -7% (-2 to12)ʻ 0.004
Cortical atrophy d = 0.3 0.001 Sex, age, edu, BP, PVD, smoking, BMI, HL
Subcortical atrophy d = 0.3  ʻ 0.03
Cortical density loss: range 4.3 - 5.0% <0.001
Subcortical density loss: 5.2% <0.001
Sulcal widening: mean diff -0.3  0.3
Ventricular enlargement: mean diff 0.5 <0.03
Ventricular enlargement: NS NS No
Any cerebral atrophy: OR 3.4 (1.8 - 6.5)  ʻ ? No
Cortical atrophy: d = range -0.2 to 0.7 (right temporal horn)ʻ NS
Subcortical atrophy: d = range 0.2 to 0.4  ʻ NS
Any cerebral atrophy: OR 3.2 (2.3 - 4.4)ʻ <0.05 No
Cortical atrophy: mean diff 1.5 (0 - 2.5) ?
Subcortical atrophy: mean diff 0 (-1.5 to 2) NS
Medial temporal lobe atrophy: mean diff 0.5 (-0.5 to 0.5) NS
Age, sex
Age, head size
No
Age, sex, edu, 
Age, sex, PVD
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Table 4. Meta-analyses white matter lesions and lacunar infarcts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PET and SPECT studies 
Four studies examined cerebral perfusion in DM with SPECT49-52. Three of 
these studies involved patients with DM1 (mean ages 30-40 years; population 
sizes 20-65)49-51 observing both modest regional hypo- and hyperperfusion in 
the DM patients relative to controls, particularly in patients with longstanding 
DM and with a history of severe hypoglycaemic episodes. The fourth study that 
predominantly involved patients with DM2 observed 25% to 30% reductions in 
mean cerebral blood flow in all cortical areas studied, and the cerebellum, in a 
group of 27 patients (mean age 64 years) relative to age-matched controls52. 
The abnormalities were most pronounced in patients that were treated with 
insulin52. A study in DM1 patients with Xenon-enhanced CT reported CBF to 
be in the normal range in most patients, but did observe reduced flow with 
increased duration of DM53. 
 
One study on 21 patients with DM1 and 12 controls reported a 15-20% 
reduction in cerebral glucose metabolism in DM1 with PET, but only in a 
subgroup of patients with longstanding DM and microvascular complications 
(neuropathy, retinopathy)54. No abnormalities in glucose metabolism were 
observed in patients with newly diagnosed DM54. 
Control (n) DM (n)
Vascular cohorts CT 5 2129 604 1.1 (0.9-1.4)
Outpatient cohorts MRI – PVH 2 1024 86 1.8 (0.9-3.6)
MRI – DWML 2 1024 86 1.7 (0.9-3.5)
MRI - any WML 2 4071 246 2.4 (1.7-3.4)
Lacunar infarcts
General cohorts MRI 3 5281 708 1.3 (1.1-1.6)
Vascular cohorts CT 5 1349 338 2.3 (1.8-3.0)
MRI 7 4389 888 2.1 (1.8-2.5)
Total (CT + MRI) 12 5738 1226 2.2 (1.9-2.5)
Outpatient cohorts MRI 4 3934 291 1.4 (1.1-1.8)
Imaging measure* Studies (n) Subjects OR†
† Odds ratios (OR) are presented with 95% CI within brackets. 
For WML, all studies that could be included in the meta-analysis are marked in table 1. The analysis on 
lacunar infarcts includes all studies listed in table 2.
White matter lesions
Analyses were performed on the crude, unadjusted data. 
* DWML = deep white matter lesions, PVH = periventricular hyperintensities, “any WML”  includes 
studies that did not distinguish between DWML and PVH.
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Discussion 
 
The CT and MRI studies reviewed herein show a relation between DM and 
cerebral atrophy and lacunar infarcts, but no consistent relation with WML. The 
MRS studies report elevated myo-inositol-to-creatine ratios and reduced N-
acetylaspartate-to-creatine ratios in DM patients. The PET and SPECT studies 
reveal regional alterations in cerebral blood flow. None of the studies assessed 
the relation between imaging findings and cognition, and data on the relation 
between imaging findings and disease variables were scarce. 
 
Methodological limitations were observed in a considerable proportion of 
studies. Study design and methodology were markedly heterogeneous, invol-
ving issues such as sample selection, DM assessment, imaging rating methods 
and data analyses. The majority of the studies based their results on relatively 
small populations. This leads to low statistical power, as illustrated by the 
power calculations in table 2. The findings from negative studies may therefore 
reflect lack of power instead of lack of associations. Selective recruitment may 
also have confounded the results. For example, patients with more severe brain 
lesions are less likely to participate in imaging studies. Moreover, the results of 
the studies belonging to the “vascular” or “outpatient cohorts” have a low 
external validity and cannot readily be generalized to the DM population at 
large. The results of the meta-analysis support this point: the risk estimates for 
lacunar infarction, for example, clearly differ between the studies from the 
“vascular cohorts” and the “general and outpatient cohorts”.  All but one study 
had a cross-sectional design. A longitudinal design with repeated brain imaging 
could detect progression of brain abnormalities and would provide a better 
indication of their relation with DM. A high response rate on follow-up is 
needed to overcome selective (related to both the determinant and the outcome) 
participation. 
 
The methodology for the diagnosis and classification of DM was suboptimal in 
the majority of the studies. Undiagnosed cases of DM will therefore have been 
erroneously assigned to the non-diabetic group, which can lead to an under-
estimation of the effect of DM. A distinction into DM type was usually not 
made. The majority of the CT and MRI studies are likely to have predo-
minantly included DM2 patients, based on the age of the study populations. 
PET and SPECT studies, in contrast, mainly involved DM1 patients. The 
relevance of the PET and SPECT findings for the CT and MRI abnormalities 
can therefore be questioned (and vice versa). It should be considered that DM1 
and DM2 may have different effects on the brain. DM2, for example, is closely 
linked to the so-called metabolic syndrome, which refers to a cluster of vascular 
risk factors, including hypertension, obesity, insulin resistance and dyslipid-
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aemia, which may each affect the brain55. Hypoglycaemic episodes, on the 
other hand, are more common in DM1 patients and may also have detrimental 
effects, albeit through entirely different pathophysiological mechanisms. 
 
Limitations concerning the rating methods for the imaging data were also 
noted, in particular in studies on WML. The majority of the WML scales that 
were applied were originally developed for patients with cerebrovascular 
disease or vascular dementia, and are relatively crude and insensitive. Although 
these scales adequately distinguish between patients with or without severe 
WML, they could be too insensitive to detect differences in WML between 
patients with DM and controls. True volumetric scales should be used in future 
studies56. The same applies to measurement of cerebral atrophy, but apparently 
the association between DM and atrophy is more robust and has therefore been 
more consistently detected even with relatively crude techniques. A possible 
methodological limitation of the PET and SPECT studies is failure to account 
for cerebral atrophy, which may have confounded the assessment of tracer 
uptake due to partial volume effects57. 
 
The included studies herein provide leads on the pathogenesis, but do leave 
many questions unanswered. The MRI and CT studies clearly identify DM as a 
risk factor for vascular brain pathology, in particular infarctions. The 
mechanisms underlying cerebral atrophy, however, cannot be readily deter-
mined from cross-sectional imaging studies. Along these lines, specific causa-
tive mechanisms cannot be derived from elevated myo-inositol levels and 
decreased  N-acetylaspartate levels on 1H-MRS studies48. PET and SPECT 
studies point at disturbances of both cerebral blood flow and glucose meta-
bolism. However, blood flow changes were regional, included both hypo- and 
hyperperfusion, and were mostly limited to subgroups of patients. It is still 
uncertain whether these changes are cause or consequence of alterations in 
cerebral function in DM. 
 
The lack of information on risk factors for brain imaging abnormalities also 
hampers the identification of underlying mechanisms. Only a minority of the 
studies included in this review took the effects of vascular risk factors, such as 
hypertension or atherosclerosis, into account, which should be regarded as an 
important omission. In the general population, hypertension, atherosclerosis 
and markers of inflammation are established risk factors for WML and lacunar 
infarcts58-60. Although cerebral atrophy is generally assumed to be due to 
neurodegenerative processes, it is also associated with vascular risk factors33,61. 
It could therefore be argued that vascular (co)morbidity is the driving force in 
the association between DM and brain imaging abnormalities, but this appears 
to be an oversimplification. A recent population based study (proportion of DM 
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patients <10%) indicated that increased HbA1c levels are associated with 
accelerated cerebral atrophy, while taking into account vascular risk factors62. 
This is in line with observation from studies on cognitive functioning in DM 
patients, which also indicate that chronic hyperglycaemia may have detrimental 
effects on the brain3-5. 
 
In conclusion, there is convincing evidence for an association between DM and 
cerebral atrophy and lacunar infarcts, but the risk factors for these brain 
imaging abnormalities have not yet been identified, and the relation with 
impaired cognition has not been addressed. In addition, the issue on the 
association between DM and WML is not yet settled, as the methodology of 
available studies was not sufficiently sensitive to detect subtle alterations. 
Future studies should have a longitudinal design and include sufficiently large 
groups of well defined DM patients preferably at an early stage of the disease 
in order to detect incident structural brain changes. MRI is the preferred 
imaging modality, because the abnormalities are subtle, and rating methods 
should be sensitive and quantitative (e.g. 3D volumetry). Patients should be 
without cognitive impairment at study entry to assess causality with cognitive 
function. Standardized neuropsychological examinations should be performed 
at regular intervals and data on relevant disease variables and co-morbidity 
should be carefully recorded in order to identify the risk factors for structural 
brain changes. PET, SPECT and MRS may help to identify underlying 
metabolic and vascular mechanisms. 
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Abstract 
 
Background and purpose: 
Diabetes Mellitus (DM) type 2 has been associated with poor cognitive 
performance and dementia, particularly in the elderly patients. The exact 
mechanisms underlying the cognitive dysfunction in DM remain unclear.  
Imaging studies of the brain could be helpful to give more insight into possible 
structural brain lesions underlying this cognitive dysfunction. Therefore, we 
performed a study in independently living patients with DM type 2 in order to 
investigate the association between DM and brain imaging abnormalities. 
 
Methods: 
The study population consisted of 45 patients with DM type 2 without 
hypertension (mean age 73.2±5.1 years, mean duration 16.7±11.4 years), 45 
patients with DM type 2 and hypertension (mean age 73.3±5.9 years, mean 
duration 11.3±9.1 years) and 44 control subjects (mean age 73.0±5.3 years). All 
patients and control subjects underwent an MRI of the brain. White matter 
lesions (WML), cerebral atrophy and medial temporal lobe atrophy (MTA) 
were rated by a standardized visual rating scale. Lacunar infarcts were defined 
as focal hypointensities on FLAIR sequences with a hyperintense rim around it. 
 
Results: 
WML occurred more frequently in diabetic patients with hypertension as well 
as without hypertension. Significantly more deep white matter lesions 
(DWML) were found in DM patients with and without hypertension when 
compared to control subjects, whereas no difference was found in the 
occurrence of periventricular hyperintensities (PVH). In all 3 groups lacunar 
infarcts occurred sporadically. A trend towards higher atrophy scores was seen 
in patients with DM compared to control subjects. 
 
Conclusions: 
The data of this cross-sectional study suggest that type 2 DM is an independent 
risk factor for deep WML in the independently living elderly patients. 
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Introduction 
 
Diabetes Mellitus (DM) has been associated with cognitive impairment and 
dementia, particularly in the elderly1. The exact cerebral mechanisms 
underlying these cognitive deficits remain unclear but brain atrophy and 
vascular changes have both been assumed. Although a significant relation 
between DM and cortical or subcortical atrophy has been found in several 
studies, the results with regard to the relation of DM and white matter lesions 
(WML) or lacunar infarcts are conflicting2-10. Reasons for these inconsistencies 
are methodological problems, like the number of patients studied, the use of 
insensitive rating scales to assess WML and patient selection. Moreover, most 
studies were not specifically designed to assess the effects of DM on structural 
brain lesions, but were performed in a group of selected patients who already 
suffered from a stroke2,5,7,9. In addition, a distinction into type 1 or type 2 DM 
was usually not made in most studies, while they may have different effects on 
the brain. Often type 2 DM typically develops in the context of a cluster of 
vascular and metabolic risk factors, like hypertension, dyslipidaemia and 
obesity, also called the “metabolic syndrome”, which each could lead to brain 
damage itself. Hypertension, indeed, is the most consistent risk factor 
associated with WML and has been reported to increase the risk for WML 
approximately two fold11-13. More detailed insight into structural brain 
abnormalities that may underlie changes in cognition in diabetic patients could 
provide important clues into the pathogenesis.  
Therefore, we performed a study in a well-defined group of independently 
living elderly patients with type 2 DM to investigate the association between 
type 2 DM, WML, lacunar infarcts and brain atrophy. Furthermore we 
compared diabetic patients with and without hypertension to assess if 
concomitant hypertension could be defined as a relevant disease variable in DM 
patients or if DM is an independent risk factor.  
 
 
Methods 
 
The study population consisted of 45 type 2 DM patients with hypertension, 45 
type 2 DM without hypertension, and 44 control subjects without DM and 
without hypertension. DM patients were recruited from the department internal 
medicine in the Sint Lucas Andreas hospital during a time period from 2001 to 
2004. The diagnosis of DM was made according to the WHO criteria14. 
 
Control subjects were age-matched healthy partners or neurological outpatients, 
visiting the hospital for low back pain or a peripheral nerve problem. Control 
subjects were without cardiovascular or metabolic disorder. All were recruited 
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by the same neurologist (BvH). Exclusion criteria for patients as well as control 
subjects were cerebrovascular accidents, intracranial tumours, neurodegenera-
tive diseases and alcohol intake of >3 units/day. 
 
Information on current health status, medical history, drug prescriptions, 
smoking behaviour and level of education was obtained by means of interview. 
Educational attainment was rated on an ordinal scale ranging from 1 (incom-
plete primary) to 7 (university). Total serum cholesterol, high-density lipopro-
tein (HDL), glucose and glycosylated haemoglobin (glyco-Hb) were determi-
ned. Blood pressure was measured in upright sitting position using an aneroid 
Sphygmomanometer. Measurements were done on two different occasions with 
a minimal interval of 4 weeks. The diagnosis of hypertension was based on his-
tory or if the mean of at least two measurements was systolic ≥160 mmHg or 
diastolic ≥ 95 mmHg. 
 
Brain MRIs were obtained with a 1.5 Tesla scan (General Electric, Milwaukee, 
USA). Whole brain axial and coronal fluid attenuated inversion recovery 
(FLAIR) and axial T2-weighted were acquired to allow detailed visualization 
of WML and lacunar infarcts. Coronal FLAIR images and sagittal T1-weighted 
images were acquired to allow measurement of medial temporal lobe atrophy 
(MTA) and whole brain volume. The MRI scans were analyzed by an 
experienced rater (PhS) who was blinded to all clinical information. The 
Scheltens’ scale was used to assess periventricular hyperintensities (PVH), 
white matter hyperintensities (WMH), basal ganglia hyperintensities (BGH) 
and infratentorial foci of hyperintensities (IFH)15. The PVH were examined in 
three regions, frontal and occipital gaps and periventricular bands, which were 
rated as follows: none (score 0); 5 mm or less (score 1); 6 mm or greater (score 
2). The WMH were examined in four regions of the brain, the temporal, frontal, 
parietal, and occipital lobes, which were rated as follows: none (score 0); 3 mm 
and less and five or less lesions (score 1); 3 mm or less and six ore more lesions 
(score 2); 4 to 10 mm and five or less lesions (score 3); 4 to 10 mm and six or 
more lesions (score 4); 11 mm or greater and one or more lesions (score 5); and 
large confluent lesions (score 6). The BHG were examined in five regions of 
the basal ganglia, the head of the caudate, putamen, globus pallidus, thalamus, 
and internal and external capsule (scores similar to the WMH). The IFH were 
examined in four regions of the infratentorial structures, the cerebellum, 
mesencephalon, pons and medulla with scores similar to the WMH. Total 
scores and subscores were used for analysis, whereby a total of deep white 
matter lesions (DWML) was derived by summing WMH and BGH scores. The 
presence of PVH and DWML is illustrated in figure 1. 
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1a.  1b.   1c 1d. 
Figure 1 Examples of periventricular hyperintensities (open arrows), deep white matter 
lesions (white arrows) (a,b,c) and lacunar infarcts (d) on axial fluid attenu-
ated inversion recovery (FLAIR) sequences. 
 
Cerebral atrophy and MTA were measured by a five point visual rating 
scale16,17. Mean scores of left and right MTA were used for analysis. Lacunar 
infarcts were defined as focal hypointensities corresponding on FLAIR 
sequences with a hyperintense rim around it (figure 1d). Distinction from 
dilated perivascular spaces was made on the basis of location, size and shape of 
the hypointense abnormalities. The number of patients with lacunar infarcts 
(n≥1) was used for analysis. 
 
Statistical analysis: 
Data were analyzed with SPSS for Windows statistical package (release 12.0, 
SPSS, Chicago, IL). Baseline differences between groups were assessed using 
independent samples t-tests and [Chi]2 tests as appropriate. Non-parametric 
tests were used for comparison of WML, lacunar infarcts, MTA and cerebral 
atrophy. Correlations were computed with the Spearman’s correlation 
coefficient. All statistical tests were two-tailed and significance was accepted at 
a level of p<0.05. 
 
 
Results 
 
The groups were comparable with regard to sociodemographic factors and 
lipoprotein levels (table 1, see page 64). The mean systolic pressure was 
significantly higher in the DM group with hypertension. The mean duration of 
DM was significantly longer in patients without hypertension. MRI data were 
inconclusive in 2 patients due to claustrophobia. The total WML score was 
statistically significantly higher in DM patients compared to control subjects 
(p=0.02) (table 2, see page 64). DWML occurred more frequently in patients 
with DM (p=0.007), whereas the occurrence of PVH did not (p=0.3). The total 
amount of WML and DWML showed higher scores in DM patients with 
hypertension compared to those without, but significance was not reached 
(p=0.74 and p=0.91 respectively). 
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Table 1. Characteristics of the study population 
 
Table 2. Prevalence of WML, lacunar infarcts and atrophy between the different groups. 
 
DM with 
hypertension
DM without 
hypertension
Control subjects
Total WML score 5.9 (5.6)* 5.4 (3.7)* 3.3 (2.4)
PVH 2.5 (1.5) 2.8 (1.6) 2.2 (1.4)
DWML 3.3 (4.4)* 2.6 (2.5)* 1.2 (1.4)
IFH 0.1 (0.4) 0.0 (0.1) 0 (0)
Lacunar infarcts (N patients) 5 3 3
MTA 0.38 (0.56) 0.44 (0.70) 0.28 (0.55)
Global atrophy 1.0 (0.5) 1.2 (0.7) 0.9 (0.6)
Kruskal-Wallis tests were performed for the analysis of WML and atrophy, Chi-square tests for the 
differences of lacunar infarcts; * signifies p<0.05 compared to control group.
PVH =  periventricular hyperintensities, DWML = deep white matter lesions, IFH = infrantentorial foci of 
hyperintensities.
Values of the WML total score, subscores, medial temporal lobe atrophy (MTA) and global atrophy 
scores are expressed as means (SD).
The lacunar infarcts are expressed as the number of patients with lacunar infarcts; 
DM with 
hypertension
DM without 
hypertension
Control subjects
Number 45 45 44
Age 73.5 (6.1) 73.4 (5.1) 73.1 (5.4)
Sex m/v 19/26 21/24 21/23
Duration of DM 11.9 (9.2)# 16.5 (11.5) -
Education, median 4.0 4.0 4.5
Smoking behaviour (yes/no) 3/42 7/38 7/38
Atrial fibrillation (N) 4 4 0
RR systolic 155 (19)*# 136 (12) 144 (14.9)
RR diastolic 80 (10)# 75 (7)* 83 (8)
Cholesterol/HDL 4.8 (1.3) 4.2 (1.4) 4.5 (1.4)
Glyco-Hb 7.7 (1.0)* 7.8 (1.0)* 5.8 (1.1)
OAD/insulin 9/36 14/31 --
Data are expressed as means (SD), analyses were done with ANOVA with posthoc Bonferroni tests, Chi 
square tests or Kruskal-Wallis tests when appropriate; * signifies p<0.05 compared to the control group; # 
signifies p<0.05 compared to the other patient group; OAD signifies oral anti-diabetics
DM = Diabetes Mellitus, OAD = oral anti-diabetics, BP = blood pressure, HDL = high density lipoprotein
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The prevalence of lacunar infarcts in all 3 groups was low without significant  
differences (p=0.68) (table 2). Although atrophy scores tended to be higher in 
the DM group a statistically significant association was not found for MTA 
(p=0.48) or global atrophy (p=0.25) (table 2). A significant positive correlation 
was found between the value of glyco-Hb and total WML score (r = 0.25, p = 
0.02) as well as DWML score (r = 0.25, p = 0.02). The correlation of glyco-Hb 
with PVH was not significant. The duration of DM correlated significantly with 
PVH (r=0.24, p=0.03), DWML (r=0.28, p=0.01) and total WML score (r=0.29, 
p=0.008). 
 
 
Discussion 
 
We found more DWML in a group of independently living elderly patients with 
type 2 DM compared to healthy control subjects. A relation between DM and 
lacunar infarcts and DM and atrophy was not found. No significant differences 
were found between the DM groups with and without hypertension. The 
significantly positive correlation between the duration of DM and WML may 
explain the non-significant differences in findings between diabetic patients 
with and without hypertension. To strengthen the association between type 2 
DM and DWML we found significantly positive correlations between the 
severity of DWML and the value of glyco-Hb and the duration of DM 
respectively. 
 
A number of studies addressing the association between DM and WML have 
been published previously with inconsistent results. We have chosen a case-
control study design consisting of independently living elderly outpatients with 
type 2 DM, which may have implications for these specific patients. Our results 
with regard to DWML are in line with a recently published study in a group of 
patients with type 2 DM recruited from general practioners, but in contrast to 
our study differences in atrophy scores were also significant18. Two other 
relatively small case-control studies have shown conflicting results with regard 
to DM and WML, but only patients with type 1 DM were included19,20. Two 
population-based studies demonstrated a relation of DM with cerebral atrophy, 
whereas an association with WML was not found3,6. Most other studies used 
dichotomous or ordinal rating scales, which may be not sensitive enough in the 
discrimination between various degrees of WML2,7-10. This might be important, 
because the consistently reported modest cognitive deficits in DM patients do 
not suggest severe lesions and the used scales may therefore underestimate 
WML in DM patients1. The Scheltens’ scale, on the contrary, which was used 
in the present study, is able to detect small amount of WML15. Furthermore, 
other studies were not designed to specifically assess the effects of DM on 
neuroimaging modalities, but assessed the effect of DM in selected patients 
with stroke or other cardiovascular riskfactors2,5,7,9. The results of these studies 
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have low external validity and do not allow to generalize to the DM population, 
which are visiting an outpatient clinic. 
 
The difference between the association of DM with DWML versus PVH 
supports the hypothesis that DWML and PVH are pathologically different. It 
has already been suggested that PVH is more associated with atrophic proces-
ses involving ventricular enlargement whereas DWML is associated with cere-
brovascular risk factors21,22. 
 
The results of the present study may be important to provide clues for the 
pathogenesis of cognitive impairment in DM patients. To our knowledge only 
one study analyzed cognitive function and brain imaging within a type 2 DM 
population and found some associations between cognitive function and brain 
MRI abnormalities18. 
 
Among the limitations of the present study is firstly the use of a visual rating 
scale for assessing atrophy. Although visual rating of MTA is a clinically useful 
method for differentiating Alzheimer’s disease from controls and is quicker and 
more accurate than volumetry23, volumetric scales may be more sensitive in our 
study population without clinically diagnosed dementia. This may explain the 
non-significant trend towards higher atrophy scores in DM patients compared 
to controls. Secondly, actual volumetric assessments may be more sensitive to 
assess WML, but in fact a significant agreement of the Scheltens’ scale with 
quantitative volumetric measurements has been shown, so results are not 
expected to differ much when volumetry had been used 24. Finally, the 
prevalence of lacunar infarcts was low and may therefore explain the non-
significant differences in the DM patients with hypertension compared to those 
without as well as the control subjects due to lack of statistical power. 
 
In conclusion, the data of this cross-sectional study show that type 2 DM is an 
independent risk factor for DWML in the independently living elderly patients. 
The significantly positive correlation between the value of glyco-Hb and the 
severity of WML may have important therapeutical implications suggesting 
that better metabolic control in the elderly patients with type 2 DM could 
prevent worsening of WML. Further studies are needed to investigate the 
relations between MRI measures and cognitive decline in DM patients. 
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Abstract 
 
 
Background: 
Exact mechanisms underlying cognitive dysfunction in Diabetes Mellitus (DM) 
remain unclear. Imaging studies of the brain could help to identify possible 
structural brain lesions underlying cognitive dysfunction. 
 
Objective: 
To describe a detailed neuropsychological profile in patients functioning inde-
pendently with type 2 DM. Secondly, correlations were studied between cogni-
tive impairment and brain lesions on magnetic resonance imaging (MRI), i.e. 
periventricular hyperintensities (PVH), deep white matter lesions (DWML), 
medial temporal lobe atrophy (MTA), cerebral atrophy and lacunar infarcts. In 
addition, the influence of relevant disease variables of DM was studied. 
 
Methods: 
92 patients with type 2 DM (mean age 73.2±5.7 years, mean duration 
13.8±10.8 years) and 44 control subjects (mean age 72.9±5.3 years) were 
included and underwent an extensive neuropsychological test battery and an 
MRI of the brain. 
 
Results: 
Neuropsychological scores were worse for each cognitive domain except for 
memory functions after adjustment for hypertension in a group of elderly pa-
tients with type 2 DM compared to healthy control subjects. Only PVH were 
independently associated with motor speed, whereas all other MRI measures 
were not independently associated with cognitive impairment. Interactions be-
tween the different MRI measures were not present. Glycosylated haemoglobin 
(HbA1c) and duration of DM were significantly associated with cognitive dys-
function. 
 
Conclusions: 
The data of this cross-sectional study show that type 2 DM is associated with 
diminished cognitive function in different cognitive domains, while memory is 
less affected after adjustment for hypertension. The association of cognitive 
impairment with MRI measures is equivocal, whereas HbA1c and duration of 
DM were significantly associated with cognitive dysfunction. 
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Introduction 
 
Type 2 Diabetes Mellitus (DM) is a common condition in the elderly and has 
been associated with cognitive impairment and dementia1-4. The majority of 
studies investigating cognitive impairment associated with type 2 DM had a 
case-control design and indicated that older DM patients perform worse than 
controls on a variety of cognitive function tests. Cognitive impairment may be 
particularly affect verbal memory or complex information processing in type 2 
DM1,3. However, study populations were mostly small and studies did not take 
into account possible differences in educational level and usually did not adjust 
for age, sex and comorbid hypertension3. In addition, most studies did not 
perform an extensive neuropsychological test battery and population studies 
more often used global cognitive screening tests like the mini mental state 
examination (MMSE)3,5. 
 
The cerebral mechanisms underlying these cognitive deficits and the 
responsible brain structures remain to be delineated and are subject of intense 
research, but brain atrophy and vascular changes have both been assumed6,7. 
Although a significant relation between DM and cortical or subcortical atrophy 
has been found in several studies, the results with regard to the relation of DM 
and white matter lesions (WML) or lacunar infarcts are conflicting8-16. These 
inconsis-tencies may be due to methodological problems, like the number of 
patients studied, the use of insensitive rating scales to assess WML or patient 
selection. In all studies no associations were investigated between cognitive 
impairment and brain imaging abnormalities in diabetic patients. 
Therefore, we performed a cross-sectional case-control study in a well-defined 
group of elderly type 2 DM patients living independently at home to describe 
the neuropsychological profile in detail. Secondly, we investigated the relation-
ship of cognitive performance to MRI measures and DM related determinants 
(e.g. glycosylated haemoglobin (HbA1c), DM duration, insulin treatment, 
hypertension, hypercholesterolemia and diabetic polyneuropathy). 
 
 
Patients and methods 
 
The study population consisted of 92 patients with type 2 DM, which were 
recruited from the department internal medicine in the Sint Lucas Andreas hos-
pital during a time period from 2001 to 2004 and 44 control subjects. For 
inclusion all patients and control subjects had to be 60 years or older and diabe-
tic patients had to have a diabetic duration of at least 1 year. Patients were 
recruited irrespective of the presence of cognitive complaints. Control subjects 
were age-matched healthy spouses or neurological outpatients, visiting the 
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hospital for low back pain or a peripheral nerve problem. Control subjects were 
without a history of cardiovascular or metabolic disorder. All were recruited by 
the same neurologist (BvH). Exclusion criteria for patients as well as control 
subjects were a psychiatric or neurologic disorder (unrelated to type 2 DM) that 
could influence cognitive function, cerebrovascular accidents, a history of alco-
hol or substance abuse and dementia. Control subjects were excluded if they 
had a blood glucose of ≥ 7.0 mmol/l. All participants were functioning 
independently at home and had intact comprehension of the Dutch language. 
The study was approved by the local Medical Ethical Committee. All subjects 
gave informed consent. 
Information on current health status, medical history, drug prescriptions, 
smoking behaviour and level of education was obtained by means of interview. 
Information on the presence or absence of hypertension in the diabetic popu-
lation was obtained by studying the medical records. Educational attainment 
was rated on an ordinal scale ranging from 1 (incomplete primary school) to 7 
(university degree). Total serum cholesterol/high-density lipoprotein (HDL) 
ratio, glucose and HbA1c were determined. Blood pressure was measured in 
upright sitting position using an aneroid sphygmomanometer, which was 
calibrated regularly. Measurements were done on two different occasions with 
a minimal interval of 4 weeks. The diagnosis of hypertension in all patients and 
control subjects was based either on history and the use of antihypertensive 
medication or if the mean of at least two measurements was systolic ≥160 
mmHg or diastolic ≥ 95 mmHg17,18. A diagnosis of polyneuropathy was based 
on history and physical exam. 
 
Cognitive assessment 
A subjective memory questionnaire consisting of 24 questions based on the 
Memory Assessment Clinic rating scales (MAC) was used to obtain 
information on subjective cognitive function19,20. All information was collected 
without the help of a proxy. 
Objective cognitive assessment included global cognitive screening tests and an 
extensive neuropsychological test battery. Global cognitive functioning was 
assessed using the HIV Dementia Scale (HDS)21, the Cognitive part of the 
Cambridge Examination for Mental Disorders of the Elderly22, which incor-
porates the Cambridge Cognitive Examination (CAMCOG) and the Mini Men-
tal State Examination (MMSE)23. In addition, a battery of standardized neuro-
psychological tests was administered in order to further characterize the nature 
of cognitive dysfunction. The examiner was blind to the status (diabetic or non-
diabetic) of the patients. Tests of executive functioning included Controlled 
Oral Word Association Test (COWAT), category fluency (animals, jobs)24, 
Trail making test B25 and Stroop color/word test part III, including the errors26. 
The score of trailmaking test B divided by trailmaking A and the subtraction 
score of Stroop colour/word test part III-part II were used for analysis. Memory 
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was evaluated using Rey Auditory Verbal Learning Test (RAVLT, immediate 
and delayed recall)27 and Rivermead Behavioural Memory Test (RBMT) 
Logical Memory test (immediate and delayed recall)28. Speed of mental 
processing was assessed with the Trail making test part A, Stroop colour/word 
test part I and II. Tests of motor functions included Grooved Pegboard test (GP 
dominant and non-dominant hand29) and the binary choice reaction time of the 
FEPSY30. In order to reduce the number of variables, four composite scores 
were constituted by calculating the mean of the standardized z-scores across the 
whole study sample in each domain. The scales were first reversed to 
correspond with each other. A negative score always represented a lower per-
formance. The validity of this test classification was found to be satisfactory 
(Cronbach’s alpha > 0.6 for each cognitive domain). 
 
Brain imaging 
Brain MRIs were obtained with a 1.5 Tesla scan (1.5 Tesla, General Electric, 
Milwaukee, USA). Whole brain axial and coronal fluid attenuated inversion 
recovery (FLAIR) and axial T2-weighted were acquired to allow detailed visu-
alization of WML and lacunar infarcts. Coronal FLAIR images and sagittal T1-
weighted images were acquired to allow measurement of medial temporal lobe 
atrophy (MTA) and cerebral atrophy. The MRI scans were analyzed by an 
experienced rater (PhS) who was blinded to all clinical information. The 
Scheltens’ scale was used to assess periventricular hyperintensities (PVH), 
white matter hyperintensities (WMH), basal ganglia hyperintensities (BGH) 
and infratentorial foci of hyperintensities31. Total scores and subscores were 
used for analysis, whereby a total of deep WML (DWML) was derived by 
summing WMH and BGH scores. 
Cerebral atrophy and MTA were measured by a five point visual rating 
scale32,33. Mean scores of left and right MTA were used for analysis. Lacunar 
infarcts were defined as focal hyperintensities corresponding to cerebrospinal 
fluid on FLAIR and T2 sequences (<5mm). The number of patients with 
lacunar infarcts (n≥1) was used for analysis. 
 
Statistical analysis 
Data were analyzed with SPSS for Windows statistical package (release 12.0, 
SPSS, Chicago, IL). Baseline differences between groups were assessed using 
independent samples t-tests, Mann-Whitney U tests and [Chi]2 tests as appro-
priate. Neuropsychological test performance was studied using analysis of 
variance (ANOVA) with sex, age, education and hypertension as covariates. 
Magnitude of effect size (Cohen’s d) for each cognitive domain and individual 
neuropsychological test was calculated as the mean group difference divided by 
the pooled standard deviation34; a negligible effect is defined if d ≤ 0.2, a small 
effect if 0.2 < d ≤ 0.5, a medium effect if 0.5 <d ≤ 0.8 and a large effect if d > 
0.8. 
Multiple linear regression analyses were performed to examine independent 
associations between MRI measures and cognitive impairment in the diabetic 
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population. The different cognitive domains were used as the dependent varia-
bles and the MRI measures were the independent variables. In addition, age, 
sex, education and hypertension were entered as covariates. WML (low/high) 
and atrophy scores (low/high) were dichotomized at the respective sample 
medians. Interactions between the different MRI lesions were tested with 
ANOVA. A second linear regression analysis was performed to investigate 
relationships between the cognitive domains and DM disease variables. All 
statistical tests were two-tailed and significance was accepted at a level of 
p<0.05. 
 
 
Results 
 
Table 1. Characteristics of the study population The groups were comparable with 
regard to sociodemographic factors, 
systolic blood pressure and 
cholesterol/HDL (table 1). Diastolic 
blood pressure was lower in DM 
patients compared to control sub-
jects. Due to technical problems 
data for the motor tests were not 
available in 16 patients. The neuro-
psychological test results are 
presented in table 2. MRI data were 
inconclusive in 2 patients due to 
claustrophobia and 8 patients 
withdrew from MRI study. No 
differences were detected in the 
subjective memory scale between 
both groups and the composite z 
score of the memory functions, 
whereas all global test scores and 
other composite z scores differed 
significantly in the diabetes group 
compared to control patients with 
small to medium effect sizes. When hypertension was not controlled the patient 
group also differed significantly in memory functions (results not shown). The 
results were also analysed by using the raw scores of the neuropsychological 
tests. ANOVA with age, sex, education and hypertension as covariates revealed 
lower scores in diabetic patients on all tests with small to medium effect sizes. 
Significance was reached on verbal fluency (jobs category), letter fluency, 
delayed recall of RBMT, GP dominant hand and GP nondominant hand (table 
2). 
Type 2 DM Control subjects
Number 92 44
Age (years (s.d.)) 73.2 (5.7) 72.9 (5.3)
Sex m/v 40/52 20/24
Duration of DM(years (s.d.)) 13.8 (10.8) -
Education (median) 4.0 (1.6) 4.5 (1.5)
Current smokers (yes/no) 9/83 6/38
Hypertension (N) 49* 4
Systolic BP mmHg 147 (18) 143 (15)
Diastolic BP mmHg 79 (9)* 83 (8)
Cholesterol/HDL 4.4 (1.4) 4.6 (1.4)
HbA1c 7.7 (1.0)* 5.7 (1.1)
DM treatment:
OAD (N) 24
Insulin (N) 66
Diet (N) 1
DM = Diabetes Mellitus, OAD = oral anti-diabetics, BP = blood 
pressure, HDL = high density lipoprotein.  Data are expressed as 
means (SD) unless otherwise mentioned, analyses were done with 
ANOVA, Chi square tests or Kruskal-Wallis tests when appropriate; 
* signifies p<0.05 compared to the control group
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Table 2. Results of the subjective memory questionnaire, global cognitive functioning tests, 
different cognitive domains and individual neuropsychological tests 
Multiple linear regression analyses were performed to investigate the indepen-
dent contribution of PVH, DWML, MTA, global atrophy and lacunar infarcts 
to impairment in several cognitive domains (table 3, see page 76). In addition, 
age, sex, education and hypertension were entered as covariates in all analyses. 
Only PVH was independently associated with motor speed (β=-0.269, p=0.04), 
whereas all other MRI measures were not associated with cognitive decline. 
Type 2 DM Control subjects p-value d
MAC 3.28 (0.40) 3.32 (0.48) 0.719
HDS 10.2 (3.7) 13.0 (3.2) 0.001 0.84
MMSE 27.2 (2.1) 28.3 (1.5) 0.026 0.65
CAMCOG 93.0 (7.5) 98.1 (9.2) 0.008 0.59
Cognitive domains:
Z executive functioning -0.106 (0.68) 0.268 (0.60) 0.014 0.37
Z memory -0.118 (0.82) 0.273 (0.83) 0.092 0.39
Z mental speed -0.133 (0.88) 0.294 (0.78) 0.035 0.43
Z motor speed -0.027 (0.77) 0.290 (0.51) 0.001 0.32
Individual tests:
Executive functions
Trailmaking test B division score (B time/ A time) 2.9 (1.3) 2.5 (0.8) 0.37 0.35
Stroop III, subtraction score (Stroop III time -Stroop II time) 88.3 (48.8) 76.1 (58.1) 0.26 0.23
Stroop III errors 4.1 (7.7) 3.1 (8.7) 0.45 0.13
Verbal fluency, animals 17.6 (5.5) 20.1 (4.8) 0.08 0.48
Verbal fluency, jobs 12.2 (4.2) 14.4 (3.2) 0.02 0.57
Letter fluency 24.8 (11.4) 32.1 (11.3) 0.01 0.65
Memory
RAVLT immediate recall 9.6 (2.8) 10.6 (2.9) 0.52 0.36
RAVLT delayed recall 7.2 (3.2) 8.6 (3.6) 0.30 0.42
RBMT immediate recall 14.9 (6.2) 17.7 (6.0) 0.06 0.46
RBMT delayed recall 10.9 (5.9) 13.7 (6.2) 0.03 0.47
Speed of mental processing
Trailmaking test A, sec 57.1 (22.5) 46.5 (21.2) 0.12 0.48
Stroop I, sec 51.9 (12.1) 47.2 (11.4) 0.05 0.40
Stroop II, sec 65.5 (16.3) 58.7 (12.3) 0.06 0.45
Speed of motor functions
Grooved Pegboard (dominant hand ), sec 105.1 (35.2) 85.1 (22.8) 0.001 0.63
Grooved Pegboard (non-dominant hand), sec 114.3 (41.6) 99.1 (27.3) 0.004 0.41
Binary choice (FEPSY), ms 653.5 (200.3) 601.4 (105.8) 0.12 0.30
MAC = Memory Assessment Clinic rating scale, HDS = HIV dementia scale, MMSE = Mini Mental State Examination, 
CAMCOG = Cambridge Cognitive Examination, d = effect size estimate, sec = seconds, ms = milliseconds..Data for the 
MAC and for the global cognitive functioning tests are expressed as means (s.d.); analyses were done with Mann Whitney U 
tests; .Data for the different cognitive domains are expressed as mean standardized values or z scores (s.d.), negative values 
always represented lower performance, data for the different individual neuropsychological tests are expressed as mean (s.d.); 
ANOVA was used for analyses with age, sex, education and hypertension as covariates. Effect sizes were expressed as 
Cohen’s d.
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There were no interactions between PVH, DWML, global atrophy, MTA and 
lacunar infarcts. 
In addition, a second linear regression analysis was performed to predict 
cognitive deterioration in DM patients with DM related determinants (e.g. 
duration of the disease, HbA1c, insulin therapy, hypertension, cholesterol/HDL 
and polyneuropathy) as the independent variables. Only the duration of DM 
was independently associated with the domain motor speed (standardized β = -
0.226; p=0.04) and HbA1c with the HDS score (standardized β = -0.217; 
p=0.015), whereas all other variables were not. 
 
Table 3. Associations between medial temporal lobe atrophy, global atrophy, deep white 
matter lesions and periventricular hyperintensities and cognitive domains in type 2 DM 
patients 
 
 
Discussion 
 
Despite the fact the patients did not express cognitive complaints we 
demonstrated that global cognitive test scores and neuropsychological scores 
were worse for each cognitive domain except for memory functions after 
adjustment for hypertension in a group of elderly independently living patients 
with type 2 DM compared to healthy control subjects. The contribution of MRI 
measures to cognitive impairment, however, was equivocal. Only PVH were 
independently associated with motor speed, whereas all other MRI measures 
were not associated with cognitive performance in the diabetic population. 
Interactions between the different MRI measures were not present. HbA1c and 
the duration of DM were significantly associated with some cognitive 
dysfunction whereas the other DM related determinants were not. 
 
Other studies showed different results with regard to neuropsychological test 
scores between subjects with type 2 DM and controls3,5. Important reasons 
Adjusted R2 β pvh β dwml β MTA β global atrophy β lacunar 
infarcts
MMSE 0.828 0 0.105 0.072 -0.058 -0.124
CAMCOG 0.164 0.076 0.204 -0.019 -0.112 -0.107
HDS 0.368 0.036 0.061 0.023 -0.034 0.049
Executive functions 0.268 -0.167 0.117 -0.100 -0.164 0.091
Memory 0.210 -0.037 0.195 -0.069 0.013 -0.004
Mental speed 0.177 -0.185 0.220 0.011 -0.199 (p=0.086) -0.033
Motor speed 0.335 -0.269* 0.238 -0.080 -0.103 0.122
MMSE = Mini Mental State Examination, CAMCOG = Cambridge Cognitive Examination, HDS = HIV dementia scale. Linear 
regression analyses with cognitive domains as dependent variables were performed. PVH, DWMH, MTA, cerebral atrophy, lacunar 
infarcts, age, sex, education and hypertension were entered as independent variables. Regression coefficients were standardized to enable 
direct comparison of their effects on cognitive functions. * p<0.05.
 Cognitive Impairment and MRI Correlates in the Elderly Patients 
 77 
could be the use of different cognitive batteries and a different way of analy-
zing the results of these tests. In our study we used two analytical approaches to 
assess neuropsychological performance of DM patients, including comparison 
to healthy controls on composite measures of specific cognitive domains and 
comparison of the magnitude of deficits on individual measures. 
 
Although a critical review published in 19971 reported that the most commonly 
affected cognitive ability in subjects with type DM was verbal memory, our 
finding of a non-significant difference in memory functions after adjustment for 
hypertension is consistent with results of other studies3. Some studies found 
also non-significant differences and small or negligible effect sizes after con-
trolling for hypertension, but in general their overall cognitive assessment was 
relatively brief3,5. 
 
Recently Manschot et al. reported the results of their study on cognitive testing 
and MRI correlates in type 2 DM in patients recruited from general practio-
ners35. Our results on cognitive performance in a different population were in 
line with their results. They also found impaired cognitive performance in all 
cognitive domains in DM patients but statistically significant changes only in 
the domains executive functioning, information processing speed and memory. 
After adjustment for hypertension their results were not affected, but we sho-
wed that after adjustment for hypertension no statistically significant difference 
was found for the memory domain. Although our study population was older, 
had a longer DM duration and worse metabolic control, no associations were 
found between cognitive impairment and MRI abnormalities in the diabetic 
population except for PVH. This could be due to the fact that they included 
patients with a history of stroke, which may implicate that their study popu-
lation had more advanced cerebrovascular disease than our patients. Moreover, 
Prins et al. reported in a prospective study that white matter lesions, brain 
infarcts and generalized brain atrophy were associated with decline in infor-
mation processing speed and executive function. After exclusion of participants 
with an incident stroke some of the associations were no longer significant, 
which may indicate that stroke plays an intermediate role in the relationship 
between cerebral small vessel disease and cognitive decline36. 
 
We only found an independent association of PVH with motor speed. This 
finding is supported by other studies, which also found an association between 
cognitive dysfunction and PVH, but not with DWML, although analyses were 
not performed in DM patients37,38. However, it is important to realize that the 
definition of PVH differed in the studies39. In the present study PVH was 
defined as hyperintensities adjacent to the ventricles and not exceeding 10 mm. 
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A non-significant trend towards an association between mental speed with 
global atrophy was found, while other studies reported associations with white 
matter disease for this particular cognitive domain40,41. Our results confirm the 
suggestion that cognitive impairment in elderly subjects with type 2 DM is due 
to more complex pathology and not just cerebrovascular disease or cerebral 
atrophy7. 
 
No significant differences were detected in a subjective memory questionnaire 
between DM patients and controls. This illustrates that objective testing is 
important in diabetic patients to detect cognitive dysfunction. Global cognitive 
screening tests may be sufficient for detecting cognitive dysfunction and the 
HDS seems to be the most clinically relevant test. 
 
Associations between global cognitive function and HbA1c may suggest that 
optimal glycaemic control is necessary even in the elderly patients. Further-
more duration of the disease seems to be important in diminished motor speed 
tasks, whereas our results show that insulin treatment, diabetic polyneuropathy, 
hypertension and cholesterol/HDL were not independently associated with 
cognitive performance in type 2 DM patients. 
 
Among the limitations of our study is the lack of data on known vascular 
complications of DM. It would have been interesting to associate cognitive 
decline with other long-term complications as retinopathy, nephropathy and 
peripheral vascular disease, since some studies show a relation of retinopathy 
with vascular brain lesions and cognitive impairment. One study reported an 
association between background diabetic retinopathy and small focal white 
matter hyperintensities in the basal ganglia and significant cognitive disadvan-
tage42. Another study showed that retinopathy is independently associated with 
poor cognitive function, suggesting that cerebral microvascular disease may 
contribute to the development of cognitive impairment43. While we used visual 
rating scales more sophisticated MRI analyses, like volumetry, may reveal 
significant correlations with structural brain changes and cognitive impairment 
in DM patients. Another possible limitation is that our findings are based on 
selected outpatients. Therefore we cannot extrapolate our findings to the 
general population of type 2 DM patients. Finally, the number of DM patients 
is relatively small and these findings need to be replicated in a larger group 
preferably with a longitudinal design. 
 
In conclusion, the data of this cross-sectional study show that patients with type 
2 DM have diminished cognitive function in different cognitive domains, while 
memory is less affected after adjustment for hypertension. The association of 
cognitive impairment with MRI measures is equivocal, but may support a dual 
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pathology involving vascular disease as well as cerebral atrophy and probably 
yet unknown factors. Metabolic control of DM as well as the duration of DM 
seems to be important disease variables in the impaired cognitive performance. 
Regular assessment of cognitive function should be performed as part of the 
routine review of diabetic patients. 
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Summary and general discussion 
 
This final chapter provides a summary and discussion of the main findings of 
the studies that have been described in this thesis, with reference to results from 
other studies. The chapter concludes with a discussion of the possible 
implications of our findings and recommendations for future research. 
 
 
Summary 
 
Subcortical ischaemic vascular disease (SIVD) is an important cause of 
cognitive impairment in elderly patients. Screening and diagnostic tests are 
needed to identify these patients. The HIV dementia scale (HDS) is a reliable 
and quantitative scale for identifying HIV dementia1. The cognitive profile of 
HIV dementia has subcortical features that resemble subcortical ischaemic 
vascular disease (SIVD). The clinical syndrome is characterized by early 
impairment of attention and executive function, accompanied by a slowing of 
motor performance and information processing, while memory functions 
remain relatively intact2. 
 
Chapter 2 reported the results of an attempt to validate the HDS for elderly 
SIVD patients. The primary hypotheses were that the HDS could be used as a 
screening test in SIVD patients and that it could be used as a screening test for 
patients who have vascular risk factors. The HDS consists of four items and is 
easy to administer. All items of the HDS represent characteristics of subcortical 
cognitive functions, (i.e. psychomotor speed, concentration, executive functions 
and memory skills). Because the neuropsychological profiles of patients with 
normal pressure hydrocephalus (NPH) are identical to those of SIVD patients, 
NPH patients were also included in the study population2,3. The results of the 
study indicated that the HDS is capable of discriminating between patients with 
cognitive impairments due to SIVD or a NPH and normal control subjects in an 
older population. Patients had HDS scores of 5.1 ± 3.5 (maximum score 16), 
and control subjects had scores of 13.0± 2.4 (p < 0.0001). The results further 
showed that the HDS is of additional value for subjects whose Mini Mental 
State Examination (MMSE) scores fall within the normal range. The results of 
this study suggest that the HDS is capable of detecting cognitive impairment in 
SIVD patients and may therefore be used in clinical trials in SIVD patients or 
those who are at risk for SIVD. 
 
The central hypothesis of Chapter 3 was that a clinical neurophysiological test 
could be helpful for detecting cognitive impairment in SIVD patients. The late 
responses that are elicited by the auditory oddball paradigm are considered to 
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be related to cognitive processing4. It has been shown that the latency of the N2 
complex and the P3 is prolonged in patients with  Alzheimer’s disease,  
Parkinson’s disease, Huntington’s disease, Binswanger’s disease and  
depression5-7. Several studies have investigated the auditory oddball paradigm 
in patients with vascular white matter disease (i.e. leukoaraiosis or lacunar 
infarcts)6,8-11. These studies, however, used either a definition of cognitive 
decline that was based on DSM-IV criteria for Alzheimer’s dementia12 or tests 
of cognitive function that were not described in detail. In addition, these studies 
analyzed only the P3 wave. We attempted to determine whether the various 
deflections of the event-related potential (N1, N2 complex and P3) that are 
evoked by the auditory oddball paradigm could differentiate between patients 
who have vascular cognitive impairment (VCI) caused by SIVD in an early 
phase of the disease and age-matched control subjects. We demonstrated that 
N2 latency was significantly longer in patients with VCI (254.6 ± 25.1 
milliseconds) than it was in age-matched control subjects (235 ± 28.6 
milliseconds) (p = 0.001), whereas the latencies of P3 and N1 were not 
significantly different. The peak-to-peak amplitude of the N2 complex to the P3 
wave was significantly lower in the patient group (patients 11.5 ± 7.0 microvolt 
vs. controls 15.4 ± 9.4 microvolt, p = 0.02). White-matter lesions revealed by 
MRI were not correlated with N2 latency (r = -0.255, p = 0.3). These data show 
that the latency of the N2 complex is longer and the peak-to-peak amplitude of 
the N2 to P3 wave is lower for a well-defined group of VCI patients than it is 
for healthy control subjects. 
 
Subcortical ischaemic vascular disease incorporates both white-matter lesions 
and lacunar infarcts. While hypertension is the most important and consistent 
risk factor for white-matter lesions and lacunar infarcts, the data on the relation 
between these lesions and diabetes mellitus (DM) are not consistent. Because 
of the frequency of both SIVD and DM among elderly subjects we investigated 
the relation between DM and SIVD.  
 
Chapter 4 reports the result of a systematic review addressing the association 
between DM and structural brain-imaging abnormalities. It is known that DM 
increases the risk of cerebral large-vessel disease two to threefold. Whether 
DM is a risk factor for SIVD, including white-matter lesions and lacunar 
infarcts, remains unclear. Our systematic review addressed available data on 
brain-imaging changes in diabetic patients, as revealed by computer tomo-
graphy (CT) and magnetic resonance imaging (MRI); it also analysed studies 
that use magnetic resonance spectroscopy (MRS), positron emission tomo-
graphy (PET) and single-photon emission computer tomography (SPECT) to 
investigate the relationship between DM and abnormalities. We also assessed 
the relationship of these cerebral changes to cognition, and related disease 
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variables, including DM subtype, age and hypertension, DM duration, medi-
ation use and glycaemic control. Eligible studies were evaluated according to 
predefined inclusion criteria (i.e. clear imaging-outcome measures, a clear 
definition of DM and a sample size of at least 20 DM patients). Data on study 
design, DM type, treatment and associated comorbidity, imaging modality 
(MRI, MRS, CT, SPECT or PET) and imaging findings were extracted from 
the fifty-five articles that were included in the review. The methodology of 
these studies with regard to population selection, DM assessment, neuro-
imaging rating methods and data analyses were heterogeneous. DM was 
associated with cerebral atrophy in eight out of ten studies that investigated this 
relationship. Eight of nineteen studies reported an association between DM and 
lacunar infarcts. We found little evidence of an association with white-matter 
lesions. Studies that used PET and SPECT reported regional abnormalities of 
cerebral blood flow and cerebral glucose metabolism. None of the studies 
assessed the relationship between imaging findings and cognition. Data on the 
relationship between imaging findings and disease variables (e.g. age, 
hypertension, medication use, glycaemic control) were scarce as well. We 
concluded that DM is associated with cerebral atrophy and lacunar infarcts, but 
that the association with white-matter lesions is equivocal. 
 
Chapter 5 elaborated on the conclusions that were drawn in Chapter 4 by 
reporting results from a cross-sectional study that compared a well-defined 
population of independently living elderly patients with Type 2 DM to healthy 
control subjects in order to investigate the association between DM, white-
matter lesions, lacunar infarcts and brain atrophy. We also compared DM 
patients who had hypertension to those who did not, in order to determine 
whether concomitant hypertension could be defined as a relevant disease 
variable in DM patients. In addition, we investigated the relationship of DM to 
other disease determinants. The study population consisted of forty-five 
patients who suffered from Type 2 DM without hypertension (mean age 73.2 ± 
5.1 years, mean duration of DM 16.7 ± 11.4 years), forty-five patients with type 
2 DM and hypertension (mean age 73.3 ± 5.9 years, mean duration of DM 11.3 
± 9.1 years) and forty-four control subjects (mean age 73.0 ± 5.3 years). All 
patients and control subjects underwent MRI brain scans. White-matter lesions 
(WML), cerebral atrophy and medial temporal lobe atrophy (MTA) were rated 
using a standardized visual rating scale. WML occurred more frequently among 
DM patients (both with hypertension and without hypertension) than it did 
among healthy control subjects. Significantly more DWML (deep white-matter 
lesions) were found among DM patients (with and without hypertension) than 
were found among control subjects, although no difference was found in the 
occurrence of periventricular hyperintensities (PVH). Although higher atrophy 
scores were seen among DM patients than among control subjects, this result 
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was not significant. The association between Type 2 DM and DWML is 
supported by significant positive correlations between the severity of DWML 
and the value of glycosylated haemoglobin (HbA1c) and the duration of DM. 
Data from this cross-sectional study suggest that Type 2 DM is an independent 
risk factor for DWML in independently living elderly patients. 
 
Chapter 6 addressed the detailed neuropsychological profiles of independently 
functioning patients who have Type 2 DM. It also examined correlations 
between cognitive impairment and brain lesions (i.e. SIVD, atrophy and lacunar 
infarcts) that were revealed by MRI. The chapter discusses the influence of 
relevant disease variables. After adjusting for hypertension neuro-psychological 
scores for each cognitive domain except for memory functions were worse for a 
group of elderly patients with Type 2 DM than they were for healthy control 
subjects. Periventricular hyperintensities (PVH) were an inde-pendent predictor 
of motor speed, while none of the other MRI measures was independently 
associated with cognitive impairment. No interactions between the various MRI 
measures were found. HbA1c and duration of DM were both significantly 
associated with cognitive dysfunction. Data from this cross-sectional study 
show that Type 2 DM is associated with diminished cognitive functioning in 
various cognitive domains, while memory is less affected, after adjusting for 
hypertension. The association of cognitive impairment with MRI measures is 
equivocal, although HbA1c and duration of DM were significantly associated 
with cognitive dysfunction. 
 
 
General discussion 
 
Four major conclusions can be drawn from this thesis. First, we demonstrated 
that the HIV dementia scale (HDS) is a sensitive screening test for detecting 
cognitive impairment in patients with SIVD, and it may be useful as a 
screening test for a population of patients who have vascular risk factors. 
Second, we investigated the auditory oddball paradigm in SIVD patients, 
showing that the latency of the N2 complex is longer and the peak-to-peak 
amplitude of the N2 to P3 wave is lower among a well-defined group of VCI 
patients than among healthy control subjects. Third, Type 2 DM is an indepen-
ent risk factor for deep white-matter lesions in independently living elderly 
patients who visit an outpatient clinic. Fourth, although patients with Type 2 
DM exhibit global cognitive deterioration with memory function being less 
affected after adjustment for hypertension, independent correlations with SIVD 
or atrophy are equivocal. 
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The concept of SIVD was introduced as a homogeneous subtype of vascular 
cognitive impairment. This condition is a frequent cause of vascular cognitive 
impairment, and it is caused by small-vessel disease, which includes cerebral 
white-matter lesions (WML) and lacunar infarcts in subcortical white and grey 
matter13-15. Vascular cognitive impairment due to SIVD covers a wide spectrum 
of cognitive dysfunction, ranging from subtle and clinically often undetected 
deficits to overt dementia16. The neuropsychological profile is characterized by 
early impairment of attention and executive function, with a slowing of motor 
performance and information processing. Episodic memory is believed to be 
relatively unaffected13. Subtle clinical symptoms are often neglected by physi-
cians and both patients and physicians often consider these symptoms as 
normal signs of ageing. 
 
Most screening tests, such as the Mini Mental State Examination (MMSE), are 
not sensitive enough to detect cognitive impairment in such patients, as they 
were designed to identify cognitive symptoms, as in Alzheimer’s disease 
(AD)17. Because of the frequency with which SIVD is identified as a cause of 
vascular cognitive impairment, a brief and simple cognitive screening test 
should enable physicians to make early diagnoses and should facilitate the 
recognition of cognitive problems in patients who are at risk for SIVD. We 
demonstrated that the HIV dementia scale (HDS) discriminates between elderly 
patients with subcortical cognitive impairment due to SIVD and normal control 
subjects. The difference was still significant in a sub-analysis of patients who 
had MMSE scores of 27 or higher (Chapter 2). Nonetheless, we cannot exclude 
the possibility that the cognitive deficits in these patients were caused by 
concomitant AD. Patients with AD present with a different clinical picture, 
however, and they generally have lower MMSE scores. Our findings suggest 
that the HDS may be useful as a screening test for SIVD and that it is of 
additional value for subjects whose MMSE scores fall within the normal range. 
 
Second, the auditory oddball paradigm is a neurophysiological method for 
eliciting an event-related potential (ERP); it contains different deflections with 
the highest amplitude, usually measured at about 300 milliseconds (P3)4. The 
late responses elicited by the auditory oddball paradigm are considered related 
to cognitive processing4. Although several studies have evaluated the 
diagnostic value of the ERP for patients with dementia, these studies primarily 
investigated patients with advanced disease, even though early diagnosis is 
needed to provide adequate care and therapy5-7,18,19. In the present thesis, we 
showed that the latency of the N2 complex is prolonged and the peak-to-peak 
amplitude of the N2 complex to P3 wave is lowered in patients who suffer from 
VCI caused by SIVD (Chapter 3). One of the limitations of this study was that 
we did not include patients with Alzheimer’s disease. Although Goodin and 
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Aminoff reported that the N1 latency is prolonged in subcortical dementia as 
compared to cortical dementia, we found no prolonged N1 wave in our patients, 
as compared to the control subjects20. The patients in the study by Goodin and 
Aminoff were already suffering from advanced disease, while the patients in 
our study were clinically characterized by cognitive impairment and not 
dementia. Further studies are therefore necessary to compare the ERP that it 
evoked by the auditory oddball paradigm in patients with early Alzheimer’s 
disease to that which is evoked in patients who suffer from cognitive 
impairment due to SIVD. We could not demonstrate a significant positive cor-
relation between the severity of white-matter abnormalities, the presence of 
lacunar infarcts and the N2 latency in a subgroup of our study population who 
underwent MRI. Although this result may be explained by the small sample 
size, it may also suggest that the functional difference in N2 complex between 
the two groups is not accompanied by anatomical changes that are revealed by 
MRI. The lack of correlation is not completely surprising, as the clinical impact 
of the severity of WML on cognition is also a subject of discussion21. 
 
Third, age and hypertension have been shown to be clearly associated with 
WML on MRI. The association of WML with DM, however, is much weaker 
than its association with any of the other risk factors. Chapter 4 presented a 
review of the literature on the association between DM and brain-imaging 
changes. Studies using CT and MRI provide evidence of a relationship between 
DM and cerebral atrophy, and they suggest that lacunar infarcts are more 
common in DM patients, although the association with WML is equivocal. 
Many of these studies, however, have major methodological limitations, 
including small sample size, inability to adjust for confounding factors, unclear 
operationalization of DM and insensitive rating scales for structural brain 
changes22-26. 
 
Because of these inconsistencies and methodological shortcomings, we 
investigated MRI abnormalities in independently living elderly patients with 
Type 2 DM who were visiting an outpatient clinic. The results presented in this 
thesis confirm that Type 2 DM in elderly patients is an independent risk factor 
for deep WML (Chapter 5). In contrast to other studies, our study population 
consisted of a well-defined patient group with Type 2 DM, taking comorbid 
hypertension into account as well. In addition, we used a semi-quantitative 
rating scale to assess WML; this scale is more sensitive for detecting small 
amounts of WML than are the rating scales that have been used in many 
previous studies. Most of the WML scales that have been applied in previous 
studies were originally developed for patients with cerebrovascular disease or 
vascular dementia, and they are relatively crude and insensitive. Although these 
scales discriminates adequately between patients with severe WML and those 
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with modest or subtle abnormalities, they may not be sensitive enough to detect 
the modest differences in WML that are expected between patients with DM 
and control subjects (especially in small study populations). Nonetheless, 
although true volumetric scales claimed higher sensitivity, very few studies 
have used these techniques27,28. Furthermore, these studies revealed no more 
WML in DM patients than they did for control subjects. These studies also 
suffer from other methodological shortcomings (e.g. undefined DM subtype, no 
adjustment for other disease variables)27,28. Results regarding the association 
between DM and atrophy are more consistent in the literature23,26,29,30. We also 
found more atrophy among the DM group, but this difference was not 
statistically signi-ficant. Although this lack of difference may be due to the 
visual rating scale that was used, a comparative study between visual rating and 
volumetry concluded that visual rating is as clinically useful and sometimes 
even more accurate than volumetry31. Lacunar infarcts occurred sporadically in 
both DM patients and control subjects. This finding may be attributable to the 
fact that we investigated independently living patients who were visiting an 
outpatient clinic in the early phase of vascular disease. 
 
Fourth, Type 2 DM is common among the elderly, and it has been associated 
with cognitive impairment and dementia32-35. Study populations tend to be 
small, however, and they do not take into account possible differences in 
educational level. They also do not usually adjust for age, sex and co-morbid 
hypertension32. In addition, most studies do not include extensive 
neuropsychological test batteries, and most population studies use global cogni-
tive screenings tests, such as the MMSE. We investigated neuropsychological 
profiles in a well-defined group of elderly patients with Type 2 DM, as well as 
correlations with brain-imaging abnormalities. In particular, we hypothesized 
that cognitive impairment in Type 2 DM was caused by SIVD (Chapter 6). 
When we started our study, the association between cognition and MRI 
findings in the DM population was not known. We administered an extensive 
neuropsychological test battery to Type 2 DM patients and investigated 
associations with MRI lesions, in order to clarify the pathological mechanisms 
of cognitive impairment among these patients. We demonstrated that global 
cognitive test scores and neuropsychological scores for each cognitive domain 
except for memory functions after adjustment for hypertension were worse for 
a group of independently living elderly patients with Type 2 DM than they 
were for healthy control subjects. This result has been confirmed by other 
studies32. Nonetheless, although we have demonstrated that Type 2 DM is an 
independent risk factor for deep WML, these lesions are not independently 
associated with cognitive impairment in the diabetic population. Only PVH was 
an independent predictor for motor speed: none of the other MRI measures was 
associated with cognitive impairment. Interactions between the various MRI 
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measures were also not present. One of the limitations of this study was that we 
used a semi-quantitative visual rating scale to assess WML and a visual rating 
scale to determine atrophy. More sophisticated MRI analyses (e.g. volumetrics) 
may reveal significant correlations with structural brain changes and cognitive 
impairment in DM patients. We concluded that the association of cognitive 
impairment with MRI measures is equivocal in Type 2 DM, but that it may 
support a dual pathology involving both vascular disease and cerebral atrophy. 
It is possible that other factors that are not yet known play a role in cognitive 
impairment in patients with Type 2 DM. 
 
 
Clinical implications 
 
1. The HIV dementia scale could be used as a screening test for patients who 
are at risk for SIVD.  
Subcortical ischaemic vascular disease (SIVD) is a frequent cause of cognitive 
impairment. Most screening tests, such as the MMSE, are not sensitive enough 
to detect cognitive impairment in these patients, because they were designed to 
identify cognitive symptoms, as in AD. The results of this thesis show that the 
HIV dementia scale may be useful as a screening test for SIVD in elderly 
patients. 
  
2. Assessment of cognitive function should be performed routinely in diabetic 
patients. 
Polyneuropathy, retinopathy, nephropathy and peripheral vascular disease are 
important complications of DM, and patients with DM are routinely evaluated 
to assess the occurrence of these complications. The results of this study show 
that Type 2 DM in elderly patients is also associated with cognitive impairment 
in various cognitive domains. Regular assessment of cognitive function should 
be performed as part of the routine review of DM patients by skilled clinicians.  
 
 
Recommendations for future research 
 
1. The HIV dementia scale (HDS) is able to detect cognitive impairment in 
patients with SIVD; it may therefore be used in clinical trials involving SIVD 
patients or those who are at risk for SIVD. We did not include patients with 
mild cognitive impairment (MCI), however, or patients with early clinical 
symptoms of Alzheimer’s disease (AD). Patients with AD usually present a 
different clinical picture and tend to have lower MMSE scores. Patients with 
MCI and normal MMSE scores, however, may fail the HDS. Further research 
could evaluate the HDS for use with patients with MCI or early AD (with and 
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without vascular risk factors), in order to differentiate between MCI and AD, 
and subcortical vascular cognitive impairment. 
 
2. The latency of the N2 complex is longer and the peak-to-peak amplitude of 
the N2 to P3 wave is lower in a well-defined group of patients with VCI than it 
is in healthy control subjects. Correlations with WML on MRI could not be 
assessed. Further research is needed to clarify the pathophysiological mecha-
nism underlying the prolonged latency of the N2 complex in patients with 
cognitive impairment due to SIVD and to compare the ERP responses of these 
patients to those of patients who are suffering from early Alzheimer’s disease. 
 
3. The findings on the correlations between Type 2 DM, cognitive impairment 
and SIVD were based on selected outpatients. Although these results may be 
true for an outpatient population, we cannot extrapolate our findings to the 
general population of Type 2 DM patients. The study was also based on a 
cross-sectional design. To assess the causality of brain imaging abnormalities 
with cognitive function, patients with Type 2 DM should preferably have no 
cognitive impairment at study entry, and they should be followed regularly 
using standardized neuropsychological examinations at pre-defined intervals. 
Future research should be prospective in nature and should include large groups 
of well-defined DM patients, preferably in an early stage of the disease, in 
order to detect incidental structural brain changes. Given the fact that cerebral 
changes in DM patients are relatively subtle, MRI rating methods should be 
sensitive and quantitative (e.g. 3D volumetry). 
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Samenvatting en discussie 
 
De belangrijkste resultaten van de studies worden samengevat en in breder per-
spectief geplaatst. Implicaties worden besproken en aanbevelingen voor toe-
komstig onderzoek worden gedaan. 
 
Samenvatting 
 
De aanwezigheid van witte stofafwijkingen en lacunaire infarcten is een be-
langrijke oorzaak voor cognitieve achteruitgang bij de oudere patiënt. Er is be-
hoefte aan screeningstesten en diagnostische testen om deze patiënten te kun-
nen detecteren. De HIV dementie schaal (HDS) is een betrouwbare en sensitie-
ve test om patiënten met HIV dementie te kunnen identificeren1. Het cognitieve 
profiel van patiënten met HIV dementie is vergelijkbaar met dat van patiënten 
met ischemische veranderingen in de witte stof. De klinische presentatie wordt 
gekenmerkt door stoornissen in aandacht en uitvoerende functies, psychomoto-
re traagheid en geheugenstoornissen, waarbij de herkenning grotendeels intact 
is2. 
 
In hoofdstuk 2 wordt de HDS gevalideerd als een screeningstest in een oudere 
patiëntenpopulatie met cognitieve stoornissen ten gevolge van witte stofafwij-
kingen. De HDS bestaat uit 4 items en is makkelijk uitvoerbaar. Deze test on-
derzoekt kenmerken van cognitieve functies met een subcorticaal karakter, te 
weten pychomotore snelheid, aandacht en concentratie, uitvoerende functies en 
geheugentaken, waarbij ook de herkenning wordt getest. Patiënten met een 
“normal pressure hydrocephalus” (NPH) vertonen een identiek cognitief profiel 
en zijn derhalve ook geïncludeerd in de studie2,3. We hebben aangetoond dat de 
HDS in staat is oudere patiënten met cognitieve achteruitgang veroorzaakt door 
witte stofafwijkingen of een NPH te onderscheiden van gezonde controleperso-
nen. De gemiddelde HDS score in de patiëntengroep was 5.1 ± 3.5 (maximum 
score 16) en in de controlegroep 13.0 ± 2.4 (p< 0.0001). Tevens concludeerden 
we dat de HDS van aanvullende waarde is bij patiënten met een normale Mini 
Mental State Examination (MMSE) score.  
 
In hoofdstuk 3 testten we de hypothese dat een klinische neurofysiologische 
test behulpzaam zou kunnen zijn om patiënten met witte stofafwijkingen op te 
sporen. De late responsies die worden opgewekt door het zogenoemde “Audi-
tieve Oddball paradigma” zijn gerelateerd aan cognitieve processen4. Het is 
reeds aangetoond dat de latentietijden van de N2 en van de P3 verlengd zijn bij 
patiënten met de ziekte van Alzheimer, de ziekte van Parkinson, de ziekte van 
Huntington, de ziekte van Binswanger en een depressieve stoornis5-7. Een be-
perkt aantal studies heeft het Auditieve Oddball paradigma onderzocht in pati-
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enten met subcorticale ischemische veranderingen als leukoaraiosis en lacunai-
re infarcten6,8-11. Deze studies gebruikten echter, óf een definitie van cognitieve 
achteruitgang die gebaseerd was op de DSM-IV criteria voor de ziekte van 
Alzheimer12 óf cognitieve testen die niet nader werden besproken. Bovendien 
werd alleen de P3 potentiaal in deze studies geanalyseerd. Wij onderzochten of 
de verschillende deflecties van de “event-related” (gebeurtenis-gerelateerde) 
potentiaal opgewekt door het Auditieve Oddball paradigma patiënten met cog-
nitieve achteruitgang ten gevolge van witte stofafwijkingen kunnen onder-
scheiden van gezonde controlepersonen in een vroege fase van de ziekte. Wij 
toonden aan dat de N2 latentietijd statistisch significant verlengd is in de pati-
entengroep in vergelijking met de controlegroep (254.6 ± 25.1 ms versus 235 ± 
28.6 ms, p = 0.001), terwijl de latentietijden van de P3 potentiaal niet statistisch 
significant verschillend waren. De piek-piek amplitude gemeten van de N2 naar 
de P3 potentiaal was statistisch significant verlaagd in de patiëntengroep verge-
leken met de controlegroep (11.5 ± 7.0 µV versus 15.4 ± 9.4 µV, p = 0.02). 
Aangetoonde witte stofafwijkingen met MRI zijn niet gecorreleerd aan de N2 
latentietijden (r = -0.255, p=0.3). De resultaten tonen aan dat de latentietijd van 
het N2 complex langer is en de piek-piek amplitude van de N2 naar de P3 po-
tentiaal lager is in patiënten met cognitieve achteruitgang ten gevolge van witte 
stofafwijkingen vergeleken met gezonde controlepersonen. 
 
Aantasting van de kleine cerebrale vaten (“small-vessel disease”) resulteert in 
witte stofafwijkingen en lacunaire infarcten. Hypertensie is de belangrijkste ri-
sicofactor voor deze afwijkingen, terwijl de relatie met diabetes mellitus (DM) 
veel minder duidelijk is. Vanwege de hoge prevalentie van zowel DM als witte 
stofafwijkingen bij de oudere patiënt onderzochten wij de relatie tussen DM en 
deze vasculaire afwijkingen. 
 
In hoofdstuk 4 verrichtten wij een systematisch onderzoek van studies die de 
relatie tussen DM en structurele afwijkingen middels beeldvorming van de her-
senen hebben onderzocht. Het is bekend dat DM een risicofactor is voor een 
beroerte in het verzorgingsgebied van de grote bloedvaten en dat het risico bij 
patiënten met DM verdubbeld tot verdrievoudigd is. Het is onduidelijk of DM 
een risicofactor is voor aantasting van de kleine cerebrale bloedvaten, wat leidt 
tot witte stof afwijkingen en lacunaire infarcten. In dit systematisch onderzoek 
werden de beschikbare data geanalyseerd met betrekking tot cerebrale afwij-
kingen bij patiënten met DM die zichtbaar zijn op computer tomography (CT) 
of magnetic resonance imaging (MRI), zoals witte stofafwijkingen, atrofie en 
lacunaire infarcten. Ook werd gekeken naar de relatie tussen DM en cerebrale 
afwijkingen aangetoond met technieken als magnetic resonance spectroscopy 
(MRS), positron emission tomography (PET) en single-photon emission com-
puter tomography (SPECT). Vervolgens werd het verband onderzocht tussen de 
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cerebrale afwijkingen en cognitieve prestaties, en tussen de cerebrale afwijkin-
gen en relevante ziekte variabelen, zoals DM type, DM duur, leeftijd, bloed-
druk, antidiabetische therapie en metabole controle. Beschikbare studies moes-
ten voldoen aan tevoren gedefinieerde inclusie criteria: goed gedefinieerde uit-
komstmaten, definitie van de vaststelling van DM en een populatiegrootte van 
tenminste 20 DM patiënten. Van de 55 geïncludeerde studies werden data ver-
zameld over studie-opzet, DM type, medicamenteuze behandeling, geassoci-
eerde comorbiditeit en de gebruikte beeldvorming met bevindingen. De metho-
dologie van de studies met betrekking tot populatieselectie, het vaststellen van 
DM, schalen om afwijkingen op de beeldvormende technieken weer te geven 
en statistische analyses waren erg heterogeen. DM was geassocieerd met cere-
brale atrofie in 8 van de 10 studies. In 8 van de 19 studies werd een associatie 
tussen DM en lacunaire infarcten gevonden. Wij vonden weinig aanwijzingen 
voor een relatie tussen DM en witte stofafwijkingen. PET en SPECT studies 
vonden regionale stoornissen in de cerebrale doorbloeding en in het cerebrale 
glucosemetabolisme. Geen van de studies heeft gekeken naar de relatie tussen 
cerebrale afwijkingen op de beeldvorming en cognitie, en gegevens over de re-
latie tussen ziektevariabelen (leeftijd, hypertensie, medicatie en DM instelling) 
en cerebrale afwijkingen waren beperkt. Wij concludeerden dat DM geassoci-
eerd is met cerebrale atrofie en lacunaire infarcten, maar dat de associatie met 
witte stofafwijkingen onduidelijk is. 
 
Hoofdstuk 5 beschrijft de resultaten van een cross-sectionele studie waarbij de 
studiepopulatie bestond uit een groep oudere DM type 2 patiënten, die onaf-
hankelijk functioneren en een controlegroep. Associaties tussen DM met res-
pectievelijk witte stofafwijkingen, lacunaire infarcten en cerebrale atrofie wer-
den onderzocht. De DM patiënten werden onderverdeeld in patiënten met en 
zonder hypertensie om te beoordelen of hypertensie een belangrijke ziektevari-
abele is. Ook werden relaties met andere ziektevariabelen onderzocht. De stu-
diepopulatie bestond uit 45 DM type 2 patiënten zonder hypertensie (gemiddel-
de leeftijd 73.2 ± 5.1 jaar, gemiddelde DM duur 16.7 ± 11.4 jaar), 45 DM type 
2 patiënten met hypertensie (gemiddelde leeftijd 73.3 ± 5.9 jaar, gemiddelde 
DM duur 11.3 ± 9.1 jaar) en 44 controlepersonen (gemiddelde leeftijd 73.0 ± 
5.3 jaar). Alle patiënten en controlepersonen ondergingen een MRI hersenen. 
Witte stofafwijkingen, cerebrale atrofie en mediotemporale atrofie werden ge-
scoord met behulp van een gestandaardiseerde visuele schaal. Witte stofafwij-
kingen kwamen vaker voor in alle DM patiënten. Er was, echter, alleen een sta-
tistisch significant verschil met betrekking tot de diepe witte stofafwijkingen, 
terwijl er geen verschil werd gevonden voor periventriculaire witte stofafwij-
kingen. De atrofie scores waren hoger in de DM groep dan in de controlegroep, 
maar dit verschil was niet statistisch significant. De associatie tussen DM type 
2 en diepe witte stofafwijkingen werd verder gesteund door statistisch signifi-
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cante positieve correlatie coëfficiënten tussen ernst van de diepe witte stofaf-
wijkingen en respectievelijk geglycosyleerd hemoglobine en DM duur. De re-
sultaten van deze studie suggereren dat DM type 2 een onafhankelijke risico-
factor is voor diepe witte stofafwijkingen in oudere patiënten.  
 
Hoofdstuk 6 richt zich op het neuropsychologische profiel in DM type 2 patiën-
ten die zelfstandig functioneren. Tevens werden correlaties onderzocht tussen 
cognitieve stoornissen en afwijkingen op de MRI hersenen, i.e. witte stofafwij-
kingen, lacunaire infarcten en atrofie. De DM type 2 patiënten hadden ten op-
zichte van de controlegroep beperkingen in alle cognitieve domeinen, behalve 
in het geheugendomein na correctie voor hypertensie. De aanwezigheid van pe-
riventriculaire witte stofafwijkingen was een onafhankelijke voorspeller voor 
het domein motorische snelheid, terwijl alle andere MRI maten niet onafhanke-
lijk geassocieerd waren met cognitieve stoornissen. Er bestonden geen interac-
ties tussen de verschillende MRI maten. Geglycosyleerd hemoglobine en DM 
duur waren significant geassocieerd met cognitieve stoornissen. De data van 
deze cross-sectionele studie tonen aan dat DM type 2 geassocieerd is met 
stoornissen in verschillende cognitieve domeinen, terwijl na controle voor hy-
pertensie het geheugendomein niet meer statistisch significant verschillend was. 
Associaties tussen cognitieve stoornissen en MRI maten waren niet duidelijk, 
terwijl geglycosyleerd hemoglobine en DM duur wel statistisch significant ge-
associeerd waren met cognitieve stoornissen. 
 
 
Discussie 
 
Op basis van dit proefschrift kunnen 4 belangrijke conclusies worden getrok-
ken. Ten eerste hebben we aangetoond dat de HIV dementie schaal (HDS) een 
sensitieve screeningstest is voor de detectie van cognitieve achteruitgang bij 
patiënten met witte stofafwijkingen, en behulpzaam zou kunnen zijn als scree-
ningstest bij patiënten met vasculaire risicofactoren. Ten tweede hebben wij het 
Auditieve Oddball paradigma onderzocht in patiënten met cognitieve stoornis-
sen door witte stofafwijkingen en hebben wij aangetoond dat de N2 latentietijd 
langer is en de piek-piek amplitude van de N2-P3 golf lager is in de patiënten-
groep vergeleken met een gezonde controlegroep. Ten derde hebben we laten 
zien dat DM type 2 een onafhankelijke risicofactor is voor diepe witte stofaf-
wijkingen in oudere zelfstandig functionerende DM type 2 patiënten. Tenslotte 
konden wij aantonen dat DM type 2 patiënten een globale cognitieve achteruit-
gang vertonen, waarbij het geheugendomein het minst is aangedaan, terwijl de 
correlaties van deze cognitieve stoornissen met witte stofafwijkingen, lacunaire 
infarcten en atrofie niet duidelijk is. 
 
Chapter 8 
 
100 
Aantasting van de kleine cerebrale vaten wordt beschouwd als een homogeen 
subtype van vasculair veroorzaakte cognitieve achteruitgang (“subcortical 
ischaemic vascular disease”). Deze conditie blijkt een frequente oorzaak te zijn 
voor cognitieve achteruitgang en wordt veroorzaakt door aantasting van de 
kleine arteriolen leidend tot witte stofafwijkingen en lacunaire infarcten in de 
subcorticale witte en grijze stof13-15. 
 
Cognitieve stoornissen veroorzaakt door witte stofafwijkingen en lacunaire in-
farcten beslaan een breed spectrum aan cognitieve disfunctie dat varieert van 
geringe, vaak onopgemerkte stoornissen tot een ernstig dementiesyndroom16. 
Het neuropsychologische profiel wordt gekenmerkt door vroege achteruitgang 
in de aandachts- en uitvoerende functies met psychomotore traagheid. Het epi-
sodische geheugen is relatief gespaard gebleven13. De subtiele klinische symp-
tomen worden vaak niet herkend en worden door zowel patiënt als arts be-
schouwd als verschijnselen van normale veroudering. De meeste cognitieve 
screeningstesten, zoals de Mini Mental State Examination (MMSE), zijn niet 
sensitief genoeg om cognitieve stoornissen bij deze patiënten vast te stellen, 
omdat zij gericht zijn op herkenning van cognitieve achteruitgang zoals die 
voorkomt bij de ziekte van Alzheimer17. Vanwege het feit dat de aanwezigheid 
van witte stofafwijkingen een frequente oorzaak is van cognitieve stoornissen is 
behoefte aan een cognitieve screeningstest die de arts in staat stelt om herken-
ning van deze cognitieve stoornissen te vergemakkelijken. 
 
Wij hebben aangetoond dat de HIV dementie schaal (HDS) de oudere patiënt 
met cognitieve achteruitgang ten gevolge van witte stofafwijkingen goed kan 
onderscheiden van normale controles. Ook was het verschil statistisch signifi-
cant in een subanalyse bij patiënten met een MMSE score van 27 of hoger 
(normale score) (hoofdstuk 2). We kunnen echter niet uitsluiten dat de cogni-
tieve stoornissen veroorzaakt waren in het kader van bijvoorbeeld de ziekte van 
Alzheimer. Patiënten met de ziekte van Alzheimer hebben doorgaans een ande-
re klinische presentatie met vaak ook een lagere MMSE score. Onze bevindin-
gen suggereren dat de HDS gebruikt kan worden als een cognitieve screenings-
test bij patiënten met witte stofafwijkingen en van aanvullende waarde kan zijn 
bij patiënten met een normale MMSE score. 
 
Het Auditieve Oddball paradigma is een klinisch neurofysiologische methode 
die een event-related potentiaal (ERP) creëert. Deze potentiaal bevat verschil-
lende deflecties waarbij de hoogste amplitude gewoonlijk gemeten wordt bij 
ongeveer 300 milliseconden (P3)4. Deze late responsies zijn gerelateerd aan 
cognitieve processen4. De diagnostische waarde van deze ERP is in verscheide-
ne studies onderzocht bij patiënten met dementie. Het dementiesyndroom was 
bij de meeste patiënten echter al in een vergevorderd stadium, terwijl juist een 
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vroege diagnose van belang is om de patiënt adequate zorg en therapie te kun-
nen bieden5-7,18,19. In dit proefschrift hebben we aangetoond dat de N2 latentie-
tijd verlengd is en de piek-piek amplitude (N2-P3) verlaagd is bij patiënten met 
cognitieve stoornissen ten gevolge van witte stofafwijkingen (hoofdstuk 3). Eén 
van de studiebeperkingen is dat we geen patiënten met de ziekte van Alzheimer 
hebben geïncludeerd. Hoewel Goodin en Aminoff concludeerden dat de N1 la-
tentietijd verlengd is bij patiënten met subcorticale dementie vergeleken met 
corticale dementie hebben wij geen verlengde N1 latentietijd gevonden in de 
patiëntengroep in vergelijking met de controlegroep20. De ziekte van de patiën-
ten in de studie van Goodin en Aminoff was echter al ver voortgeschreden, 
terwijl in onze studie de patiënten cognitieve stoornissen vertoonden zonder te 
voldoen aan de criteria van een dementiesyndroom. Verdere studies zijn daar-
om ook noodzakelijk om de ERP van patiënten die zich bevinden in een vroeg 
stadium van de ziekte van Alzheimer te vergelijken met de ERP van patiënten 
met cognitieve stoornissen ten gevolge van witte stofafwijkingen. In een sub-
groep van patiënten bij wie een MRI was verricht konden wij geen relatie aan-
tonen tussen de N2 latentietijd en de ernst van de witte stofafwijkingen of de 
aanwezigheid van lacunaire infarcten. Hoewel dit resultaat verklaard zou kun-
nen worden door een te kleine studiepopulatie, kan het ook suggereren dat het 
functionele verschil tussen de groepen niet veroorzaakt wordt door de MRI af-
wijkingen. Het ontbreken van een relatie is niet onverwacht, daar de klinische 
impact van de mate van witte stofafwijkingen eveneens onduidelijk is21. 
 
Het is bekend dat leeftijd en hypertensie geassocieerd zijn met witte stofafwij-
kingen in de hersenen. De associatie van diabetes mellitus (DM) met deze af-
wijkingen is echter veel minder duidelijk. In hoofdstuk 4 wordt een overzicht 
van de literatuur gegeven met betrekking tot de associatie van DM en stucturele 
cerebrale afwijkingen. CT en MRI studies tonen een associatie tussen DM en 
cerebrale atrofie en tussen DM en lacunaire infarcten. De associatie met witte 
stofafwijkingen is echter onduidelijk. Veel studies vertonen belangrijke metho-
dologische tekortkomingen, zoals kleine studiepopulaties, onvermogen te corri-
geren voor confounders, onduidelijke definities van DM type en DM vaststel-
ling en het gebruik van methoden om afwijkingen te scoren die niet sensitief 
zijn22-26. 
 
Vanwege de inconsistenties en de methodologische tekortkomingen hebben wij 
een studie verricht die MRI afwijkingen bestudeert in een groep van oudere 
zelfstandig functionerende DM type 2 patiënten, gerekruteerd op de polikliniek 
interne geneeskunde (hoofdstuk 5). De resultaten die worden gepresenteerd in 
dit proefschrift tonen aan dat DM type 2 een onafhankelijke risicofactor is voor 
diepe witte stofafwijkingen. In tegenstelling tot veel andere studies bestaat onze 
studiepopulatie wel uit een goed gedefinieerde groep DM type 2 patiënten. Te-
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vens is ook rekening gehouden met hypertensie daar dit een bekende vasculaire 
risicofactor is voor witte stofafwijkingen. Bovendien hebben wij voor het be-
oordelen van afwijkingen een semi-kwantitatieve schaal gebruikt. De meerder-
heid van de witte stof schalen die zijn gebruikt in voorgaande studies zijn ei-
genlijk ontwikkeld voor patiënten met cerebrovasculaire aandoeningen of vas-
culaire dementie. Deze schalen zijn relatief grof en ongevoelig. Hoewel deze 
schalen een adequaat onderscheid kunnen maken tussen patiënten met ernstige 
witte stofafwijkingen en subtiele afwijkingen zijn zij mogelijk niet sensitief ge-
noeg om de kleinere verschillen in witte stofafwijkingen tussen DM patiënten 
en controlepersonen vast te stellen. Hoewel volumetrische schalen de meest ge-
voelige scoringsmethoden zijn werden deze in slechts enkele studies toegepast 
en werden in deze studies niet meer witte stofafwijkingen gevonden27,28. Me-
thodologische tekortkomingen zijn eveneens aan te wijzen in deze studies, zo-
als geen onderscheid in DM type en geen vaststelling van confounders27,28. De 
resultaten met betrekking tot de associatie tussen DM en atrofie zijn redelijk 
consistent in de literatuur23,26,29,30. Ook wij vonden meer atrofie, maar dit ver-
schil was niet statistisch significant. Dit kan het gevolg zijn van de gebruikte 
visuele scoringsmethode. Echter een studie die visuele schalen heeft vergeleken 
met volumetrie concludeerde dat visuele schalen klinisch bruikbaar zijn en 
nauwkeuriger kunnen zijn dan volumetrie31. De prevalentie van lacunaire in-
farcten was laag in onze studiepopulatie. Deze bevinding kan het gevolg zijn 
van het feit dat wij poliklinische patiënten hebben onderzocht die nog zelfstan-
dig functioneren en een polikliniek bezoeken, m.a.w. deze patiënten kunnen 
zich bevinden in een vroeg stadium van cerebrovasculaire ziekte. 
 
Tenslotte, DM type 2 is een veel voorkomende aandoening bij de oudere pati-
ent en is geassocieerd met cognitieve stoornissen en dementie32-35. De studie-
populaties waren echter meestal klein en vaak werd er geen rekening gehouden 
met verschillen in opleiding, leeftijd, geslacht en de aanwezigheid van hyper-
tensie32. Bovendien waren de cognitieve testen in de studies veelal beperkt en 
werden in populatie studies meestal globale cognitieve testen gebruikt, zoals de 
MMSE. Wij hebben het neuropsychologische profiel onderzocht in een groep 
oudere DM type 2 patiënten en hebben correlaties van cognitieve stoornissen 
met MRI afwijkingen onderzocht (hoofdstuk 6). De hypothese werd getoetst 
dat cognitieve achteruitgang in DM type 2 patiënten voornamelijk wordt ver-
oorzaakt door witte stofafwijkingen en lacunaire infarcten. Toen wij onze stu-
die begonnen was de associatie tussen cognitieve stoornissen en MRI bevindin-
gen bij DM type 2 onbekend en nooit eerder beschreven. Wij hebben een uit-
voerige neuropsychologische testbatterij gebruikt en hebben associaties met 
MRI afwijkingen onderzocht om het pathologische mechanisme dat ten grond-
slag ligt aan de cognitieve stoornissen nader te onderzoeken. Wij hebben aan-
getoond dat alle scores op screeningstesten en neuropsychologische testen 
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slechter waren in DM type 2 patiënten vergeleken met controlepersonen, maar 
dat na correctie voor hypertensie de verschillen voor het geheugen domein niet 
meer statistisch significant verschillend waren. Dit resultaat werd ook gevon-
den in andere studies32. Hoewel we aangetoond hebben dat DM type 2 een on-
afhankelijke risicofactor is voor diepe witte stofafwijkingen vonden we echter 
geen onafhankelijke relatie tussen diepe witte stofafwijkingen en cognitieve 
stoornissen in de DM populatie. Alleen periventriculaire witte stof afwijkingen 
waren geassocieerd met het domein motorische snelheid, terwijl geen van de 
andere MRI maten geassocieerd was met cognitieve stoornissen. Interacties 
tussen de verschillende MRI maten waren ook niet aanwezig. Eén van de be-
perkingen van deze studie is dat we visuele schalen hebben gebruikt om witte 
stofafwijkingen en atrofie te scoren. Volumetrische technieken zouden mis-
schien wel significante correlaties hebben aangetoond. Wij hebben geconclu-
deerd dat de associatie van cognitieve achteruitgang met MRI afwijkingen on-
duidelijk is bij DM type 2 patiënten. De cognitieve stoornissen bij DM type 2 
patiënten kunnen verklaard worden door zowel vasculaire afwijkingen als atro-
fie en mogelijk spelen andere nog onbekende factoren ook een rol. 
 
 
Klinische implicaties 
 
1. De HIV dementie schaal kan worden gebruikt als screeningstest bij patiën-
ten met risicofactoren voor witte stofafwijkingen. 
De aanwezigheid van witte stofafwijkingen en lacunaire infarcten is een fre-
quente oorzaak voor cognitieve achteruitgang. De veelvuldig gebruikte Mini 
Mental State Examination (MMSE) als meetinstrument is niet sensitief genoeg 
om cognitieve stoornissen in deze patiënten te detecteren, omdat zij gericht is 
op herkenning van cognitieve stoornissen zoals die voorkomen bij de ziekte van 
Alzheimer. De resultaten van dit proefschrift tonen dat de HIV dementie schaal 
bruikbaar kan zijn als screeningstest voor cognitieve stoornissen ten gevolge 
van witte stofafwijkingen bij oudere patiënten. 
 
2. Onderzoek van cognitieve functies zou standaard moeten worden uitge-
voerd bij diabetes patiënten  
Polyneuropathie, retinopathie, nefropathie en perifere vaatziekte zijn belangrij-
ke complicaties van diabetes mellitus. Patiënten worden routinematig gecontro-
leerd op het voorkomen van deze lange termijn complicaties. De resultaten van 
dit proefschrift tonen aan dat diabetes mellitus type 2 ook een risicofactor is 
voor cognitieve functiestoornissen. Regelmatig onderzoek naar het cognitief 
functioneren zou dan ook onderdeel moeten zijn van het screeningsprogramma 
om lange termijn complicaties op te sporen. 
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Aanbevelingen voor toekomstig onderzoek 
 
1. De HIV dementie schaal (HDS) is in staat om cognitieve stoornissen te de-
tecteren in patiënten met witte stofafwijkingen en zou daarom gebruikt kunnen 
worden in klinische trials of bij patiënten met een verhoogd risico. Patiënten 
met “mild cognitive impairment” (MCI) of met vroege symptomen van de ziek-
te van Alzheimer zijn echter niet geïncludeerd. Gewoonlijk vertonen deze pati-
enten een andere klinische presentatie en hebben zij lagere MMSE scores. Pati-
enten met MCI en een normale MMSE zouden theoretisch gezien slecht kunnen 
scoren op de HDS. De HDS moet nader onderzocht worden bij patiënten met 
MCI en de ziekte van Alzheimer met en zonder vasculaire risicofactoren. 
 
2. De N2 latentietijd is langer en de piek-piek amplitude van de N2 –P3 golf 
is lager van de auditief opgewekte event-related potentiaal bij een patiëntenpo-
pulatie met cognitieve achteruitgang ten gevolge van witte stofafwijkingen ver-
geleken met gezonde controlepersonen. Correlaties met witte stofafwijkingen 
konden echter niet worden aangetoond. Verder onderzoek is nodig om het on-
derliggende pathofysiologisch mechanisme te ontrafelen van de verlengde N2 
latentietijd. Tevens is het belangrijk om de bevindingen te vergelijken met pati-
enten met de ziekte van Alzheimer. 
 
3. De bevindingen met betrekking tot de correlaties tussen DM type 2, cogni-
tieve stoornissen en MRI afwijkingen zijn gebaseerd op een geselecteerde po-
pulatie. Hoewel de resultaten gelden voor een poliklinische populatie kunnen 
we deze bevindingen niet extrapoleren naar de algemene DM type 2 populatie. 
Bovendien gaat het om een cross-sectionele studie. Om causaliteit aan te tonen 
tussen MRI afwijkingen en cognitieve stoornissen zou de opzet van de studie 
een longitudinaal karakter moeten hebben en zouden de DM patiënten bij aan-
vang van de studie geen cognitieve stoornissen moeten hebben. Vervolgens 
zouden ze regelmatig onderzocht moeten worden met gestandaardiseerde neu-
ropsychologische testbatterijen en een MRI. Vanwege het feit dat de MRI af-
wijkingen relatief subtiel zijn in DM patiënten zouden sensitieve schalen moe-
ten worden gebruikt om afwijkingen weer te geven. 
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